Vascular Solutions 10-K 4 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Jan. 31, 2014	Jun. 28, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'VASCULAR SOLUTIONS INC	'	'
Entity Central Index Key	'0001030206	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$233,096,719
Entity Common Stock, Shares Outstanding	'	17,015,776	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$30,785,000	$11,554,000
Accounts receivable, net of reserves of $200,000 and $185,000 at December 31, 2013 and 2012, respectively	14,481,000	13,780,000
Inventories	14,002,000	13,737,000
Prepaid expenses and other	2,472,000	2,670,000
Current portion of deferred tax assets	6,000,000	6,800,000
Total current assets	67,740,000	48,541,000
Property, plant and equipment, net	16,187,000	14,756,000
Goodwill	10,532,000	10,387,000
Intangible assets, net	11,943,000	12,325,000
Deferred tax assets, net of current portion and liabilities	1,739,000	1,993,000
Total assets	108,141,000	88,002,000
Current liabilities:	'	'
Accounts payable	3,762,000	3,842,000
Accrued compensation	4,365,000	4,123,000
Accrued expenses	2,467,000	1,927,000
Accrued royalties	235,000	288,000
Current portion of deferred revenue and contingent consideration	556,000	345,000
Total current liabilities	11,385,000	10,525,000
Long-term deferred revenue and contingent consideration, net of current portion	406,000	610,000
Commitments and contingencies	'	'
Shareholders' equity:	'	'
Common stock, $0.01 par value: Authorized shares - 40,000,000 Issued and outstanding shares -16,964,953- 2013; 16,378,923 - 2012	170,000	164,000
Additional paid-in capital	92,346,000	84,160,000
Other	-1,000	-150,000
Accumulated earnings (deficit)	3,835,000	-7,307,000
Total shareholders' equity	96,350,000	76,867,000
Total liabilities and shareholders' equity	$108,141,000	$88,002,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Reserves for accounts receivable	$200,000	$185,000
Shareholders' equity:	'	'
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized (in shares)	40,000,000	40,000,000
Common stock, shares issued (in shares)	16,964,953	16,378,923
Common stock, shares outstanding (in shares)	16,964,953	16,378,923

Consolidated_Statements_of_Ear

Consolidated Statements of Earnings (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net revenue	'	'	'
Product revenue	$110,197,000	$98,036,000	$86,589,000
License and collaboration revenue	301,000	350,000	3,367,000
Total revenue	110,498,000	98,386,000	89,956,000
Product costs and operating expenses:	'	'	'
Cost of goods sold	36,156,000	32,561,000	29,844,000
Collaboration expenses	60,000	0	0
Research and development	13,191,000	11,870,000	10,240,000
Clinical and regulatory	4,408,000	4,358,000	4,332,000
Sales and marketing	27,372,000	25,777,000	24,126,000
General and administrative	8,991,000	6,522,000	4,997,000
Litigation	1,332,000	0	0
Medical device excise taxes	1,319,000	0	0
Amortization of purchased technology and intangibles	1,572,000	1,393,000	831,000
Total product costs and operating expenses	94,401,000	82,481,000	74,370,000
Operating earnings	16,097,000	15,905,000	15,586,000
Other earnings (expenses):	'	'	'
Interest earnings	0	0	16,000
Interest expense	-13,000	-13,000	-13,000
Foreign exchange gain (loss)	-1,000	0	110,000
Earnings before income taxes	16,083,000	15,892,000	15,699,000
Income tax expense	-4,941,000	-5,983,000	-5,960,000
Net earnings	$11,142,000	$9,909,000	$9,739,000
Basic net earnings per common share (in dollars per share)	$0.68	$0.62	$0.59
Diluted net earnings per common share (in dollars per share)	$0.65	$0.60	$0.57
Shares used in computing basic net earnings per common share (in shares)	16,412,322	16,003,932	16,638,078
Shares used in computing diluted net earnings per common share (in shares)	17,025,090	16,455,729	17,183,579

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Earnings (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements of Comprehensive Earnings [Abstract]	'	'	'
Net earnings	$11,142,000	$9,909,000	$9,739,000
Other comprehensive earnings (loss), net of tax of $0: Foreign currency translation adjustments	149,000	54,000	-288,000
Total comprehensive earnings	$11,291,000	$9,963,000	$9,451,000

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Earnings (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements of Comprehensive Earnings [Abstract]	'	'	'
Foreign currency translation adjustments, tax	$0	$0	$0

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Shareholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Other [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2010	$169,000	$90,805,000	$84,000	($26,955,000)	$64,103,000
Balance (in shares) at Dec. 31, 2010	16,889,360	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Exercise of stock options	1,000	348,000	0	0	349,000
Exercise of stock options (in shares)	87,190	'	'	'	'
Issuance of common stock under the Employee Stock Purchase Plan	1,000	949,000	0	0	950,000
Issuance of common stock under the Employee Stock Purchase Plan (in shares)	115,511	'	'	'	'
Stock-based compensation	3,000	2,247,000	0	0	2,250,000
Stock-based compensation (in shares)	236,252	'	'	'	'
Cancellation of common stock upon the vesting of restricted shares	-1,000	-513,000	0	0	-514,000
Cancellation of common stock upon the vesting of restricted shares (in shares)	-47,207	'	'	'	'
Repurchase of common stock under stock repurchase agreement	-9,000	-9,874,000	0	0	-9,883,000
Repurchase of common stock under stock repurchase agreement (in shares)	-902,901	'	'	'	'
Excess tax benefit from stock-based compensation	'	'	'	'	0
Comprehensive income:	'	'	'	'	'
Net earnings	0	0	0	9,739,000	9,739,000
Translation adjustment	0	0	-288,000	0	-288,000
Total comprehensive earnings	'	'	'	'	9,451,000
Balance at Dec. 31, 2011	164,000	83,962,000	-204,000	-17,216,000	66,706,000
Balance (in shares) at Dec. 31, 2011	16,378,205	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Exercise of stock options	2,000	487,000	0	0	489,000
Exercise of stock options (in shares)	157,590	'	'	'	'
Issuance of common stock under the Employee Stock Purchase Plan	1,000	1,003,000	0	0	1,004,000
Issuance of common stock under the Employee Stock Purchase Plan (in shares)	114,060	'	'	'	'
Stock-based compensation	2,000	2,981,000	0	0	2,983,000
Stock-based compensation (in shares)	213,309	'	'	'	'
Cancellation of common stock upon the vesting of restricted shares	-1,000	-651,000	0	0	-652,000
Cancellation of common stock upon the vesting of restricted shares (in shares)	-59,106	'	'	'	'
Repurchase of common stock under stock repurchase agreement	-4,000	-4,757,000	0	0	-4,761,000
Repurchase of common stock under stock repurchase agreement (in shares)	-425,135	'	'	'	'
Excess tax benefit from stock-based compensation	0	1,135,000	0	0	1,135,000
Comprehensive income:	'	'	'	'	'
Net earnings	0	0	0	9,909,000	9,909,000
Translation adjustment	0	0	54,000	0	54,000
Total comprehensive earnings	'	'	'	'	9,963,000
Balance at Dec. 31, 2012	164,000	84,160,000	-150,000	-7,307,000	76,867,000
Balance (in shares) at Dec. 31, 2012	16,378,923	'	'	'	16,378,923
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Exercise of stock options	4,000	2,780,000	0	0	2,784,000
Exercise of stock options (in shares)	354,300	'	'	'	'
Issuance of common stock under the Employee Stock Purchase Plan	1,000	1,191,000	0	0	1,192,000
Issuance of common stock under the Employee Stock Purchase Plan (in shares)	124,098	'	'	'	'
Stock-based compensation	2,000	3,341,000	0	0	3,343,000
Stock-based compensation (in shares)	183,034	'	'	'	'
Cancellation of common stock upon the vesting of restricted shares	-1,000	-1,210,000	0	0	-1,211,000
Cancellation of common stock upon the vesting of restricted shares (in shares)	-75,402	'	'	'	'
Excess tax benefit from stock-based compensation	0	2,084,000	0	0	2,084,000
Comprehensive income:	'	'	'	'	'
Net earnings	0	0	0	11,142,000	11,142,000
Translation adjustment	0	0	149,000	0	149,000
Total comprehensive earnings	'	'	'	'	11,291,000
Balance at Dec. 31, 2013	$170,000	$92,346,000	($1,000)	$3,835,000	$96,350,000
Balance (in shares) at Dec. 31, 2013	16,964,953	'	'	'	16,964,953

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating activities	'	'	'
Net earnings	$11,142,000	$9,909,000	$9,739,000
Adjustments to reconcile net earnings to net cash provided by operating activities:	'	'	'
Depreciation	2,861,000	2,158,000	2,115,000
Amortization	1,572,000	1,393,000	831,000
Stock-based compensation	3,343,000	2,983,000	2,250,000
Deferred taxes, net	3,138,000	5,287,000	5,445,000
Excess tax benefit from stock-based compensation	-2,084,000	-1,135,000	0
Loss (gain) on disposal of fixed assets	-17,000	6,000	36,000
Change in fair value of contingent consideration	-79,000	-232,000	-586,000
Change in accounts receivable allowance	15,000	35,000	-10,000
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-713,000	-2,084,000	-670,000
Inventories	-435,000	1,032,000	-2,179,000
Prepaid expenses and other	158,000	-977,000	29,000
Accounts payable	-86,000	995,000	194,000
Accrued compensation and expenses	485,000	192,000	739,000
Amortization of deferred license fees and other deferred revenue	86,000	-351,000	-3,353,000
Net cash provided by operating activities	19,386,000	19,211,000	14,580,000
Investing activities	'	'	'
Purchase of property and equipment, net	-4,234,000	-3,145,000	-2,389,000
Purchase of building and land	0	-7,986,000	0
Proceeds from the sale of equipment	22,000	10,000	0
Cash paid for acquisitions	-820,000	-7,500,000	-6,621,000
Net cash used in investing activities	-5,032,000	-18,621,000	-9,010,000
Financing activities	'	'	'
Net proceeds from the exercise of stock options	2,784,000	489,000	349,000
Net proceeds from the sale of common stock, employee stock purchase plan	1,192,000	1,004,000	950,000
Excess tax benefit from stock-based compensation	2,084,000	1,135,000	0
Repurchase of common shares	-1,211,000	-5,413,000	-10,397,000
Net cash provided by (used in) financing activities	4,849,000	-2,785,000	-9,098,000
Effect of exchange rate changes on cash and cash equivalents	28,000	23,000	-106,000
Increase (decrease) in cash and cash equivalents	19,231,000	-2,172,000	-3,634,000
Cash and cash equivalents at beginning of year	11,554,000	13,726,000	17,360,000
Cash and cash equivalents at end of year	30,785,000	11,554,000	13,726,000
Supplemental disclosure of cash flow	'	'	'
Cash paid for interest	13,000	13,000	13,000
Cash paid for federal and state income taxes	$1,673,000	$902,000	$535,000

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2013
Description of Business [Abstract]	'
Description of Business	'
	1. Description of Business
	Vascular Solutions, Inc. (the Company) is a medical device company focused on bringing clinically advanced solutions to interventional cardiologists and interventional radiologists.  The Company has three product categories as follows:
		·	Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner® catheter used to access discrete regions of the coronary anatomy and the Pronto® extraction catheters used in treating acute myocardial infarction. This category also includes products used in connection with gaining percutaneous access to the vasculature to perform minimally invasive procedures, such as micro-introducer kits.
		·	Hemostat products consist principally of blood clotting products, such as the D-Stat® Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. This category also includes our line of devices used in radial artery procedures, such as our Accumed™ wrist positioning splints and Vasc™ Band inflatable compression bands.
		·	Vein products and services consist principally of the Vari-Lase® endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST® radiofrequency vein ablation catheter.
	As a vertically-integrated medical device company, the Company generates ideas and creates new minimally invasive devices or services and then delivers these products and services to the physicians through a direct domestic sales force and an international distribution network.  The Company was incorporated in the state of Minnesota in December 1996 and began operations in February 1997.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Basis of Consolidation
	The consolidated financial statements include the accounts of Vascular Solutions, Inc. and its wholly owned subsidiary Vascular Solutions Zerusa Limited, after elimination of intercompany accounts and transactions.
	Segment Reporting
	A business segment is a distinguishable component of an enterprise that is engaged in providing an individual product or service or a group of related products or services and that is subject to risks and returns that are different from those of other business segments.  The Company’s segments have similar economic characteristics and are similar in the nature of the products sold, type of customers, methods used to distribute the Company’s products and regulatory environment.  Management believes that the Company meets the criteria for aggregating its operating segments into a single reporting segment.
	The Company uses three product categories for reporting revenue.  The following table sets forth, for the periods indicated, net revenue by product category along with the percent change from the previous year:
			For Years Ended December 31,
			2013						2012						2011
						Percent						Percent					Percent
			Net Revenue			Change			Net Revenue			Change			Net Revenue		Change
	Catheter products		$	69,936,000			14	%	$	61,262,000			16	%	$	53,040,000		27	%
	Hemostat products			23,752,000			5	%		22,676,000			(2	%)		23,065,000		(6	%)
	Vein products			16,509,000			17	%		14,098,000			34	%		10,484,000		(4	%)
	Total product revenue			110,197,000			12	%		98,036,000			13	%		86,589,000		12	%
	License & Collaboration			301,000			(14	%)		350,000			(90	%)		3,367,000		229	%
	Total Net Revenue		$	110,498,000			12	%	$	98,386,000			9	%	$	89,956,000		15	%
	Foreign Currency Translation and Transactions
	The functional currency of the company's foreign operations is the applicable local currency.  The functional currency is translated into U.S. dollars for balance sheet accounts using current exchange rates in effect as of the balance sheet date and for revenue and expense accounts using a weighted-average exchange rate during the fiscal year.  The translation adjustments are deferred as a component of other comprehensive income within the consolidated statements of comprehensive income and the consolidated statements of shareholders' equity.  Gains or losses resulting from transactions denominated in foreign currencies are included in other income, net in the consolidated statements of earnings.
	The Company sells products to an international distributor in Germany at prices denominated in Euros.  As a result, the Company is exposed to foreign exchange movements during the time between the shipment of the product and payment.  The Company currently has terms of net 60 days with this distributor under the agreement providing for payment in Euros.
	Comprehensive Earnings
	The components of comprehensive earnings are net earnings and the effects of foreign currency translation adjustments.  The accumulated other comprehensive earnings for the foreign currency translation adjustment at December 31, 2013 and 2012 was ($1,000) and ($150,000), respectively.
	Fair Value of Financial Instruments
	The carrying amount for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximates fair value due to the immediate or short-term maturity of these financial instruments.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of deferred tax assets and liabilities, as well as other amounts in the financial statements and accompanying notes.  Actual results could differ from those estimates.
	Cash and Cash Equivalents
	The Company classifies all highly liquid investments with initial maturities of three months at the date of purchase or less as cash equivalents.  Cash equivalents consist of cash and money market funds and are stated at cost, which approximates market value.  The Company deposits its cash in high quality financial institutions.  The balances, at times, may exceed federally insured limits.
	Credit Risk and Allowance for Doubtful Accounts
	The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments.  This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay.  Accounts receivable over 60 days past due are considered past due.  The Company does not accrue interest on past due accounts receivable.  Receivables are written off only after all collection attempts have failed and are based on individual credit evaluation and the specific circumstances of the customer.  At December 31, 2013 and 2012, the allowance for doubtful accounts was $150,000 and $130,000, respectively.
	All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.  The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on its balance sheet.  At December 31, 2013 and 2012, the sales and return allowance was $50,000 and $55,000, respectively.
	Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $200,000 and $185,000 at December 31, 2013 and 2012, respectively.
	Inventories
	Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market.   Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value.  Inventories are comprised of the following at December 31:
			2013			2012
	Raw materials		$	6,386,000		$	6,674,000
	Work-in-process			926,000			780,000
	Finished goods			6,690,000			6,283,000
			$	14,002,000		$	13,737,000
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost.  Depreciation is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Manufacturing equipment	1 to 8 years
	Office and computer equipment	1 to 5 years
	Furniture and fixtures	3 to 8 years
	Leasehold improvements	Shorter of useful life or remaining term of the lease
	Research and development equipment	3 to 7 years
	Building	30 years
	Impairment of Long-Lived Assets
	The Company will record impairment losses on long-lived assets when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount.  The amount of impairment loss recorded will be measured as the amount by which the carrying value of the assets exceeds the fair value of the assets.  To date, the Company has determined that no impairment of long-lived assets exists.
	Revenue Recognition
	In the United States the Company sells its products and services directly to hospitals and clinics.  Revenue is recognized in accordance with generally accepted accounting principles as outlined in Accounting Standards Codification (“ASC”) 605-10-S99, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered.  The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers.   The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.
	In all international markets, the Company sells its products to international distributors which subsequently resell the products to hospitals and clinics.  The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor.  The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor.  Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order.  Allowances are provided for estimated returns and costs at the time of shipment.  Sales and use taxes are reported on a net basis, excluding them from revenue.
	The Company’s revenues from license agreements and research collaborations are recognized when earned (see Note 14).  In accordance with ASC 605, for deliverables which contain multiple deliverables, the Company separates the deliverables into separate accounting units if they meet the following criteria: (i) the delivered items have a stand-alone value to the customer; (ii) the fair value of any undelivered items can be reliably determined; and (iii) if the arrangement includes a general right of return, delivery of the undelivered items is probable and substantially controlled by the seller.  Deliverables that do not meet these criteria are combined with one or more other deliverables into one accounting unit.  Revenue from each accounting unit is recognized based on the applicable accounting literature, primarily ASC 605.
	The Company currently has a license agreement with King Pharmaceuticals, Inc. (King), now a subsidiary of Pfizer, Inc., under which the Company licensed the exclusive rights of Thrombi-PadTM, Thrombi-Gel® and Thrombi-PasteTM products to King in exchange for a license fee.  The Company is amortizing the license fees on a straight-line basis over the projected 10 year economic life of the products.  The Company determines the economic life of the products under its license agreements by evaluating similar products the Company has launched or other similar products in the medical industry.  In addition, the Company had a five-year license agreement with Nicolai, GmbH in which the Company was amortizing the license fee on a straight-line basis over the five-year life of the agreement.  This agreement was fully amortized during 2013.
	As part of the agreements with King, the Company agreed to complete the development and conduct clinical studies for the Thrombi-Gel and Thrombi-Paste products, with the costs related to the clinical studies paid by King.  The Company was recognizing the collaboration revenue on this development agreement as it is earned in accordance with ASC 605.  On July 6, 2011, King notified the Company that King was terminating the development of the Thrombi-Paste products and terminating efforts to obtain the surgical indication for the Thrombi-Gel products (see Note 14).
	Starting in January 2012, the Company began to generate revenue from selling a reprocessing service for ClosureFAST radiofrequency catheters.  In accordance with ASC 605-45, the Company recognizes this revenue gross, with the amount paid to the supplier of the reprocessing service reflected as cost of sales.
	In addition, the Company has reviewed the provisions of ASC 808, Collaborative Arrangements, and the adoption of this ASC has had no impact on the amounts recorded under these agreements.
	Shipping and Handling Costs
	In accordance with the ASC 605-45-45, the Company includes shipping and handling revenues in net sales and shipping and handling costs in cost of goods sold.
	Research and Development Costs
	All research and development costs are charged to operations as incurred.
	Warranty Costs
	Certain of the Company’s products are covered by warranties against defects in material and workmanship for periods of up to 24 months.  The Company records a liability for warranty claims at the time of sale.  The amount of the liability is based on the amount the Company is charged from its original equipment manufacturer to cover the warranty period.  The original equipment manufacturers include a one year warranty with each product sold to
	the Company.  The Company records a liability for the uncovered warranty period offered to a customer, provided the warranty period offered exceeds the initial one year warranty period covered by the original equipment manufacturers.  Each of the Company’s manufacturer’s warranties cover the first year of service and as a result the Company’s exposure to uncovered warranty periods was minimal at December 31, 2013.
Warranty provisions and claims for the years ended December 31, 2013, 2012 and 2011, were as follows:
		2013			2012			2011
Beginning balance		$	29,000		$	23,000		$	13,000
Warranty provisions			69,000			57,000			79,000
Warranty claims			(75,000	)		(51,000	)		(69,000	)
Ending balance		$	23,000		$	29,000		$	23,000
Advertising Costs
The Company follows the policy of charging production costs of advertising to expense as incurred.  Advertising expense was $119,000, $103,000 and $71,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
Stock-Based Compensation
The Company has various types of stock-based compensation plans.  These plans are administered by the Compensation Committee of the Board of Directors, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.  Refer to Notes 8 and 9 for additional information related to these stock-based compensation plans.
The following amounts have been recognized as stock-based compensation expense in the Consolidated Statements of Operations:
		2013			2012			2011
Stock-based compensation included in:
Cost of goods sold		$	196,000		$	94,000		$	86,000
Research and development			373,000			389,000			250,000
Clinical and regulatory			322,000			313,000			239,000
Sales and marketing			858,000			941,000			825,000
General and administrative			1,594,000			1,246,000			850,000
		$	3,343,000		$	2,983,000		$	2,250,000
The Company uses the Black-Scholes option-pricing model to estimate fair value of stock-based awards with the following weighted average assumptions:
		2013			2012			2011
Stock Options and Awards:
Expected life (years)			3.6			6.5			5.5
Expected volatility			39	%		48	%		49	%
Dividend yield			0	%		0	%		0	%
Risk-free interest rate			0.86	%		1.21	%		2.12	%
Employee Stock Purchase Plan:
Expected life (years)			2			2			2
Expected volatility			29	%		32	%		34	%
Dividend yield			0	%		0	%		0	%
Risk-free interest rate			0.32	%		0.28	%		0.47	%
Restricted stock awards fair value is calculated as the market price on the date of grant for the years ended December 31, 2013, 2012 and 2011 and the fair value is amortized on a straight line basis over the requisite service period of four years for employee awards and one year for board of director awards.  The weighted average fair value of restricted stock awards granted during 2013, 2012 and 2011 was $16.31, $11.10 and $10.77, respectively.
The weighted average fair value of stock options granted with an exercise price equal to the deemed stock price on the date of grant during 2012 and 2011 was $5.41 and $4.72, respectively.  There were no stock option grants during 2013.  The weighted average fair value of stock options granted with an exercise price greater than the deemed stock price on the date of grant during 2012 was $5.11.
The Company calculates expected volatility for stock options and awards using historical volatility.  The starting point for the historical period used is based on a material change in the Company’s operations that occurred in the third quarter of 2003.  The Company uses a 10% forfeiture rate for key employees and a 15% forfeiture rate for non-key employees for stock options and awards.  The Company calculates expected volatility for employee stock purchase plan shares using historical volatility over a two-year period.  A two-year period is used to coincide with the maximum two-year offering period under the employee stock purchase plan.  The risk-free rates for the expected terms of the stock options and awards and the employee stock purchase plan is based on the U.S. Treasury yield curve in effect at the time of grant.
Income Taxes
Income taxes are accounted for under the liability method.  Deferred income taxes are provided for temporary differences between the financial reporting and the tax bases of assets and liabilities.  Deferred tax assets are reduced by a valuation allowance to the extent that realization of the related deferred tax asset is not assured.  If the Company determines in the future that it is more likely than not that the Company will realize all or a portion of the deferred tax assets, the Company will adjust the valuation allowance in the period the determination is made (see Note 7).
When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained.  The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.  Tax positions taken are not offset or aggregated with other positions.  Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority.  The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
The Company has recorded ASC 740, Income Taxes, reserves of $1,268,000 and $1,074,000 at December 31, 2013 and 2012.  The impact of tax related interest and penalties is recorded as a component of income tax expense.  At December 31, 2013, the Company has recorded $-0- for the payment of tax related interest and there were no tax penalties or interest recognized in the consolidated statements of earnings.
Net Earnings Per Common Share
In accordance with ASC 260, Earnings Per Share, basic net earnings per common share is computed by dividing net earnings by the weighted average common shares outstanding during the periods presented.  Diluted net earnings per common share is computed by dividing net earnings by the weighted average common and potential dilutive common shares outstanding computed in accordance with the treasury stock method.
The number of shares used in earnings per share computations is as follows for the years ended December 31:
		2013			2012			2011
Weighted average common shares outstanding— basic			16,412,322			16,003,932			16,638,078
Effect of dilutive securities			612,768			451,797			545,501
Weighted average common shares outstanding— diluted			17,025,090			16,455,729			17,183,579
The effect of dilutive securities in the above table excludes -0-, 270,000 and 70,000 of options for which the exercise price was higher than the average market price for the years ended December 31, 2013, 2012 and 2011, respectively.
Goodwill and Other Intangible Assets
Goodwill is reviewed for impairment annually on December 31st or more frequently if changes in circumstances or the occurrence of events suggest impairment exists using a two-step process.  In step 0, the Company can elect to perform an optional quantitative analysis and based on the results, skip the remaining two steps.  Consistent with prior years, in the current year the Company chose to skip step 0 and perform a quantitative analysis in Step 1.  In the step 1, the fair value of each reporting unit is compared to its carrying value, including goodwill.  If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized.  If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and the Company would then complete step 2 in order to measure the impairment loss.  In step 2, the Company would calculate the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets (including unrecognized intangible assets) of the reporting unit from the fair value of the reporting unit.  If the implied fair value of goodwill is less than the carrying value of goodwill, the Company would recognize an impairment loss, in the period identified, equal to the difference.  The Company has concluded that no impairment of goodwill existed as of December 31, 2013.
Other intangible assets consist of purchased technology, trademark/tradenames, developed technology, customer relationships and licenses.  The Company reviewed intangible assets for impairment as changes in circumstances or the occurrence of events suggested the remaining value was not recoverable.
Amortization on the intangibles is provided on a straight-line basis over the estimated useful lives of the assets as follows:
Trademark/tradename	10 to 11 years
Purchased and developed technology	9 to 11 years
Customer relationships	9 years
Licenses	5 to 10 years
Leases and Deferred Rent
On November 30, 2012, the Company closed on the purchase of an office building located next to the building which previously housed the Company’s principal executive offices.  The Company occupies approximately 23,000 square feet of the building and leases the remaining 47,000 square feet of the building to third-party tenants.
In addition, during the year ended December 31, 2013 the Company also leased additional office and manufacturing space.  Leases are accounted for under the provisions of ASC 840, Leases, which requires that leases be evaluated and classified as operating or capital leases for financial reporting purposes.  As of December 31, 2013, all of the Company’s leases were accounted for as operating leases.  For leases that contain rent escalations, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between the rents paid and the straight-line rent as a deferred rent.  For any lease incentives the Company receives for items such as leasehold improvements, the Company records a deferred credit for the amount of the lease incentive and amortizes it over the lease term, which may or may not equal the amortization period of the leasehold improvements in accordance with ASC 840-20.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Goodwill and Other Intangible Assets	'
	3. Goodwill and Other Intangible Assets
	The Company acquired trademark/tradename, developed technology and customer relationships most recently from the following (see Note 15):
		·	Zerusa Limited in January 2011,
		·	Accumed Systems, Inc. (Accumed) in June 2012,
		·	St. Jude Medical in August 2012, and
		·	Shepherd Scientific, Inc. (Shepherd Scientific) in December 2012
	The Company is amortizing these intangibles over their useful lives of 9 to 11 years.  The goodwill acquired in the same transactions will not be amortized.  In December 2011, the Company acquired the exclusive right to sell reprocessing services for ClosureFAST radiofrequency catheters in the U.S. and is amortizing the cost over the five year term of the license (see Note 15).  In January 2012, the Company acquired the rights, patents and intellectual property relating to a two-lumen catheter for distal protection and material extraction used in the Company’s Pronto catheters (see Note 15).  In September 2013, the Company entered into a services agreement with Northeast Scientific, Inc. to obtain FDA approval for reprocessing another medical device (see Note 15).  Amortization expense was $1,572,000, $1,393,000 and $831,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	Balances of acquired intangible assets as of December 31, 2013 were as follows:
			Carrying			Accumulated		Net
			Amount			Amortization
	Amortizing intangibles:
	Purchased and developed technology		$	8,140,000		$	2,360,000	$	5,780,000
	Purchased licenses			5,050,000			1,010,000		4,040,000
	Trademark / tradename			2,210,000			592,000		1,618,000
	Customer relationships			640,000			133,000		507,000
	Foreign currency translation adjustments			16,000			18,000		(2,000	)
			$	16,056,000		$	4,113,000	$	11,943,000
	Balances of acquired intangible assets as of December 31, 2012 were as follows:
			Carrying			Accumulated		Net
			Amount			Amortization
	Amortizing intangibles:
	Purchased and developed technology		$	7,960,000		$	1,555,000	$	6,405,000
	Purchased licenses			4,150,000			505,000		3,645,000
	Trademark / tradename			2,170,000			390,000		1,780,000
	Customer relationships			620,000			74,000		546,000
	Foreign currency translation adjustments			(50,000	)		1,000		(51,000	)
			$	14,850,000		$	2,525,000	$	12,325,000
	Based on the intangibles assets as of December 31, 2013, future amortization expense was as follows:
	2014		$	1,734,000
	2015			1,824,000
	2016			1,817,000
	2017			1,644,000
	2018			1,644,000
	Thereafter			3,280,000
			$	11,943,000
	The following table provides a summary of additions and disposals of goodwill for each reporting period:
	Balance at December 31, 2011		$	8,117,000
	Acquisition of Accumed wrist positioning splint			562,000
	Acquisition of St. Jude Medical’s Venture wire control catheter			1,444,000
	Acquisition of Shepherd Scientific’s AngioAssist & Teirstein Edge			210,000
	Foreign currency translation adjustments			54,000
	Balance at December 31, 2012		$	10,387,000
	Acquisition of Disposable Vein Hook			59,000
	Foreign currency translation adjustments			86,000
	Balance at December 31, 2013		$	10,532,000

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	4. Property, Plant and Equipment
	Property, plant and equipment consist of the following at December 31:
		2013			2012
	Plant and equipment:
	Manufacturing equipment	$	12,019,000		$	10,174,000
	Buildings		6,407,000			6,407,000
	Office and computer equipment		2,798,000			2,265,000
	Research and development equipment		2,567,000			1,707,000
	Leasehold improvements		2,489,000			2,269,000
	Furniture and fixtures		1,039,000			782,000
	Building improvements		665,000			–
	Construction-in-process		658,000			977,000
			28,642,000			24,581,000
	Less accumulated depreciation and amortization		(14,055,000	)		(11,425,000	)
	Net plant and equipment		14,587,000			13,156,000
	Land		1,600,000			1,600,000
	Net property, plant and equipment	$	16,187,000		$	14,756,000

Lines_of_Credit

Lines of Credit	12 Months Ended
	Dec. 31, 2013
Lines of Credit [Abstract]	'
Lines of Credit	'
	5. Lines of Credit
	As of December 31, 2013, the Company had a secured asset-based revolving credit agreement with U.S. Bank National Association dated December 21, 2009 (as amended on December 6, 2012; December 20, 2011 and December 20, 2010).  The revolving credit agreement was a one-year, $10,000,000 facility with availability based primarily on eligible customer receivables, inventory and property and equipment.
	The revolving credit agreement required a quarterly payment based on an annual fee of 0.125% of the average unused portion of the committed revolving line as determined by the bank and reviewed by management.
	The revolving credit agreement included one covenant that the Company cannot have a maximum cash flow leverage ratio greater than 2.5 to 1.  The calculation of this covenant is determined by multiplying annual lease expense times six and adding any loans, then dividing this amount by the sum of earnings before interest, taxes, depreciation, amortization and annual operating lease payments.  The covenant is computed quarterly based on a rolling 12-month period.  The Company was in compliance with the covenant as of December 31, 2013.
	As of and through-out the year ended December 31, 2013, the Company had no outstanding balance against the revolving credit agreement.  The revolving credit agreement expired on December 31, 2013 and has not been renewed.

Leases

Leases	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Leases	'
	6. Leases
	The Company leases two buildings in Minnesota totaling approximately 106,000 square-feet under an operating lease.  The lease continues to remain in effect through September 2015 with an option to renew.  The Company leases one building in Ireland totaling approximately 1,150 square feet.  This lease is scheduled to expire in July 2014, however it does contain extension provisions.  Rent expense related to the operating leases was approximately $1,350,000, $1,273,000 and $1,297,000 for the years ended December 31, 2013, 2012, and 2011, respectively.
	Future minimum lease commitments under the operating leases as of December 31, 2013 were as follows:
	2014	$	908,000
	2015		682,000
	2016		–
	2017		–
	2018		–
	Thereafter		–
		$	1,590,000

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
	7. Income Taxes
	At December 31, 2013, the Company had recorded the following components of deferred taxes with a finite life:
					Expiration
		2013			Date
	Federal and Minnesota research and development tax credit carryforwards	$	4,766,000		Beginning in 2014
	Foreign research and development tax credit carryforwards		93,000		Do not expire
	Foreign operations operating loss carryforwards		643,000		Do not expire
	The Company has recorded an allowance of approximately $144,000 relating to those research and development tax credit carryforwards expected to expire prior to utilization.
	The Company is subject to income tax in numerous jurisdictions and at various rates and the use of estimates is required in determining the provision for income taxes.  For the year ended December 31, 2013, the Company recorded tax expense of $4,941,000 on earnings before tax of $16,083,000 resulting in an effective income tax rate of 31%.  For the year ended December 31, 2013, income before taxes relating to U.S. operations was $16,080,000, while the loss from foreign operations was $108,000.  For the year ended December 31, 2012, the Company recorded tax expense of $5,983,000 on earnings before tax of $15,892,000 resulting in an effective income tax rate of 38%.  For the year ended December 31, 2012, income before taxes relating to U.S. operations was $15,594,000, while income before tax from foreign operations was $298,000.
	The Company is subject to income tax examinations in the U.S. Federal jurisdiction, as well as in the Republic of Ireland and various state jurisdictions.  U.S. Federal tax years that remain open to examination at December 31, 2013 are 2010 through 2013 and state tax years that remain open to examination at December 31, 2013 are 2009 through 2013.
	A reconciliation of the beginning and ending amount of unrecognized tax benefit is as follows:
	Balance at December 31, 2011	$	1,020,000
	Increases as a result of tax positions taken during a prior period		–
	Increases as a result of tax positions taken during the current period		54,000
	Reductions as a result of lapse of the applicable statute of limitations		–
	Decreases relating to settlements with taxing authorities		–
	Balance at December 31, 2012	$	1,074,000
	Increases as a result of tax positions taken during a prior period		–
	Increases as a result of tax positions taken during the current period		223,000
	Reductions as a result of lapse of the applicable statute of limitations		(29,000	)
	Decreases relating to settlements with taxing authorities		–
	Balance at December 31, 2013	$	1,268,000
	The components of the Company’s deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows:
		2013				2012
	Deferred tax assets:
	Tax credit carryforwards	$	4,766,000			$	5,610,000
	Stock-based compensation		1,151,000				1,514,000
	Net operating loss carryforwards		–				1,288,000
	Federal and state AMT credits		985,000				996,000
	Inventory reserve		609,000				557,000
	Depreciation and amortization		624,000				520,000
	Accrued compensation		578,000				487,000
	Deferred revenue		229,000				320,000
	Legal settlement		196,000				–
	Foreign operations net operating loss carryforwards		96,000				47,000
	Other		115,000				130,000
	Gross deferred tax assets		9,349,000				11,469,000
	Deferred tax liability relating to amortization		(584,000	)			(336,000	)
	Net deferred taxes assets before reserve for uncertain tax positions and valuation allowances		8,765,000				11,133,000
	Reserve for uncertain tax positions		(882,000	)			(906,000	)
	Less valuation allowances		(144,000	)			(1,434,000	)
	Net deferred tax asset	$	7,739,000			$	8,793,000
		2013				2012
	Deferred taxes recorded on the balance sheet:
	Net deferred tax assets – current	$	6,000,000			$	6,800,000
	Net deferred tax assets – long-term		1,739,000				1,993,000
	Net deferred tax assets	$	7,739,000			$	8,793,000
	The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable earnings.  At December 31, 2013 and 2012, the valuation allowance was $144,000 and $1,434,000, respectively.  The increase (decrease) in the valuation allowance was ($1,290,000), ($683,000) and $185,000 for the years ended December 31, 2013, 2012 and 2011, respectively.  For the years ended December 31, 2013 and 2012, the Company recorded stock option and employee stock purchase plan tax deductions of $2,116,000 and $1,181,000, respectively.  For the year ended December 31, 2013 and 2012, the Company recorded stock option and employee stock purchase plan tax benefits against “additional paid-in capital” and reduced taxes payable by a corresponding amount of $2,084,000 and $1,135,000, respectively.
	Reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		2013				2012			2011
	Tax at statutory rate		34	%			34	%		34	%
	State income taxes, net of federal benefit		4.4				6.2			5.8
	Permanent differences		(0.8	)			1.9			1.2
	Change in valuation reserve		0.2				0.2			(1.1	)
	R&D credits generated		(4.2	)			(1.1	)		(3.1	)
	Reserve for uncertain tax positions		0.9				0.1			0.6
	Foreign operations tax rate difference		(0.5	)			(0.7	)		–
	Disallowed federal R&D credits at 12.31.12		(1.9	)			–			–
	Other adjustments		(1.0	)			(3.0	)		0.6
	Effective income tax rate		31.1	%			37.6	%		38	%
		2013				2012			2011
	Current taxes		26.8	%			12.8	%		3.8	%
	Deferred taxes		6.6				26.1			34.7
Benefit from foreign operation tax rates		(0.5	)			(0.7	)		–
Benefit from domestic manufacturers deduction		(1.8	)			(0.6	)		(0.5	)
Effective income tax rate		31.1	%			37.6	%		38	%

Stock_Options_and_Restricted_S

Stock Options and Restricted Shares	12 Months Ended
	Dec. 31, 2013
Stock Options and Restricted Shares [Abstract]	'
Stock Options and Restricted Shares	'
	8. Stock Options and Restricted Shares
	Stock Option and Stock Award Plan
	The Company has a stock option and stock award plan (the Stock Option Plan) which provides for the granting of stock options, restricted shares and stock appreciation rights to employees, directors, and consultants.  Incentive stock options may be granted only to employees of the Company.  Options which do not qualify as incentive stock options and awards of restricted shares may be granted to both employees and to non-employee directors and consultants.  As of December 31, 2013, the Company had reserved 5,500,000 shares of common stock under the Stock Option Plan.  Under the Stock Option Plan, stock options must be granted at an exercise price not less than the fair market value of the Company’s common stock on the grant date.  Vesting requirements of all awards under this plan are time based and vary by individual grant.  The options expire on the date determined by the Board of Directors but may not extend more than 10 years from the grant date.  The incentive stock options generally become exercisable over a four-year period and the nonqualified stock options generally become exercisable over a one-year period.  Vested and unexercised options are canceled three-months after termination, and unvested awards are canceled on the date of termination of employment and become available under the Stock Option Plan for future grants.
	Prior to 2013 the Company granted annual stock options to its directors under the Stock Option Plan.  The ten-year options issued to the Company’s directors vest over a one-year period based on the continuation of service as a director of the Company.  The Company used a 0% forfeiture rate for all director options granted.
	In January 2012, the Company granted stock options to the chief executive officer under the Stock Option Plan.  The ten-year options issued to the Company’s chief executive officer vest over five successive one-year periods based on the continuation of service with the Company and contain a $1 per share escalation in the exercise price each year.  The Company used a 0% forfeiture rate for this option grant.
	Option activity is summarized as follows:
	Shares
	Available
	for Grant						Weighted
	(exclusive of						Average		Aggregate
	restricted		Plan Options		Exercise		Exercise		Intrinsic
		shares issued)			Outstanding			Price			Price			Value
	Balance at December 31, 2010		3,878,000			837,000		$	0.78–$10.98		$	6.62
	Shares reserved		500,000			–			–			–
	Granted		(70,000	)		70,000			11.72			11.72
	Exercised		–			(87,000	)		0.84– 9.46			4
	Forfeited		–			–			–			–
	Expired		19,000			(19,000	)		0.84– 9.46			5.45
	Balance at December 31, 2011		4,327,000			801,000		$	0.78–$11.72		$	7.38
	Shares reserved		(1,900,000	)		–			–			–
	Granted		(500,000	)		500,000			11.03– 15.03			12.89
	Exercised		–			(158,000	)		0.84– 10.28			3.1
	Forfeited		–			–			–			–
	Expired		–			–			–			–
	Balance at December 31, 2012		1,927,000			1,143,000		$	0.78–$15.03		$	10.38
	Shares reserved		500,000			–			–			–
	Granted		–			–			–			–
	Exercised		–			(354,000	)		0.78– 11.72			7.86
	Forfeited		–			–			–			–
	Expired		1,000			(1,000	)		0.84– 5.74			5.38
	Balance at December 31, 2013		2,428,000			788,000		$	6.36–$15.03		$	11.52		$	9,164,000
	Exercisable at December 31, 2013					421,000					$	9.8		$	5,625,000
	The number of common shares available for the grant of future stock awards is limited to 1,021,000 common shares.  The shares available for grant number disclosed in the table above does not include 1,407,000 common shares issued in the form of restricted shares.
	The weighted average remaining contractual term of options exercisable at December 31, 2013, was 4.8 years. The total intrinsic value of options exercised during fiscal 2013, 2012 and 2011, was $3,057,000, $1,464,000 and $677,000, respectively.
	The following table summarizes information about stock options outstanding at December 31, 2013:
			Options Outstanding									Options Exercisable
						Weighted
			Outstanding			Average			Weighted			Exercisable
			as of			Remaining			Average			as of			Weighted
	Range of		December 31,			Contractual			Exercise			December 31,			Average
	Exercise Prices		2013			Life			Price			2013			Exercise Price
	$ 6.36–$ 7.88			76,000			3.9		$	6.83			76,000		$	6.83
	7.89– 9.46			115,000			1.5			9.44			115,000			9.44
	9.47– 10.98			67,000			4.2			10.08			67,000			10.08
	10.99– 12.03			260,000			8			11.58			163,000			11.32
	12.04– 13.03			90,000			8.1			13.03			–			–
	13.04– 15.03			180,000			8.1			14.53			–			–
				788,000			6.3		$	11.52			421,000		$	9.8
	As of December 31, 2013, there was $1,287,000 of total unrecognized compensation costs related to the outstanding stock options, which is expected to be recognized over a weighted average period of 3.08 years.
	The holder of a restricted share award is generally entitled at all times on and after the date of issuance of the restricted shares to exercise the rights of a shareholder of the Company, including the right to vote the shares and the right to receive dividends on the shares.  These shareholders do not have the ability to sell, transfer or otherwise encumber the restricted share awards until they fully vest.  During 2013, 2012 and 2011, the Company granted restricted shares to directors and employees under the Stock Option Plan.  The restricted shares granted to employees of the Company vest over a four-year period based on the continuation of employment.  The restricted shares granted to the Company’s director’s vest over a one-year period based on the continuation of service as a director.
	Restricted share activity is summarized as follows:
					Weighted Average
					Grant Date Fair
		Shares
		Outstanding			Value
	Balance at December 31, 2010		463,000		$	8.49
	Granted		274,000			10.77
	Vested		(132,000	)		8.72
	Forfeited		(38,000	)		10.05
	Balance at December 31, 2011		567,000		$	9.43
	Granted		245,000			11.1
	Vested		(167,000	)		8.12
	Forfeited		(32,000	)		10.67
Balance at December 31, 2012		613,000		$	10.39
Granted		199,000			16.31
Vested		(208,000	)		9.96
Forfeited		(16,000	)		11.22
Balance at December 31, 2013		588,000		$	12.52
As of December 31, 2013, there was $2,010,000 of total unrecognized compensation costs related to the outstanding restricted shares, which is expected to be recognized over a weighted average period of 1.01 years.
The Company estimates the forfeiture rate for restricted stock using 0% for directors, 10% for key employees and 15% for non-key employees.

Employee_Stock_Purchase_Plan

Employee Stock Purchase Plan	12 Months Ended
	Dec. 31, 2013
Employee Stock Purchase Plan [Abstract]	'
Employee Stock Purchase Plan	'
	9. Employee Stock Purchase Plan
	The Company has an Employee Stock Purchase Plan (the Purchase Plan) under which 2,700,000 shares of common stock have been reserved for issuance.  Eligible employees may contribute 1% to 10% of their compensation to purchase shares of the Company’s common stock at a discount of 15% of the market value at certain plan-defined dates, up to a maximum of 2,000 shares per purchasing period.  The Purchase Plan terminates in July 2020. In fiscal 2013, 2012 and 2011, 124,100 shares, 114,100 shares, and 115,500 shares, respectively, were issued under the Purchase Plan.  At December 31, 2013, 965,000 shares were available for issuance under the Purchase Plan.
	As of December 31, 2013, there was $340,000 of total unrecognized compensation costs related to the Purchase Plan, which is expected to be recognized over a weighted average period of 0.80 years.

Employee_Retirement_Savings_Pl

Employee Retirement Savings Plan	12 Months Ended
	Dec. 31, 2013
Employee Retirement Savings Plan [Abstract]	'
Employee Retirement Savings Plan	'
	10. Employee Retirement Savings Plan
	The Company has an employee 401(k) retirement savings plan (the Plan).  The Plan provides eligible employees with an opportunity to make tax-deferred contributions into a long-term investment and savings program.  All employees over the age of 21 are eligible to participate in the Plan beginning with the first quarterly open enrollment date following start of employment.  The Plan allows eligible employees to contribute up to 50% of their annual compensation, subject to a maximum limit determined by the Internal Revenue Service, with the Company contributing an amount equal to 25% of the first 5% contributed to the Plan.  The Company recorded an expense of $243,000, $204,000 and $194,000 for contributions to the Plan for the years ended December 31, 2013, 2012, and 2011, respectively.

Concentrations_of_Credit_and_O

Concentrations of Credit and Other Risks	12 Months Ended
	Dec. 31, 2013
Concentrations of Credit and Other Risks [Abstract]	'
Concentrations of Credit and Other Risks	'
	11. Concentrations of Credit and Other Risks
	In the United States the Company sells its products directly to hospitals and clinics.  In all international markets, the Company sells its products to distributors who, in turn, sell to hospitals and clinics.  Loss, termination, or ineffectiveness of distributors to effectively promote the Company’s product could have a material adverse effect on the Company’s financial condition and results of operations.
	No customer represented more than 10% of total revenue for any year ended December 31, 2013, 2012 and 2011.
	The Company performs credit evaluations of its customers and does not require collateral to extend credit to an account.  No customer represented more than 10% of gross accounts receivable at December 31, 2013 and 2012. There have been no material losses on customer receivables.
	Product revenue by geographic destination as a percentage of total product revenues were as follows for the years ended December 31:
		2013			2012			2011
	Domestic		85	%		84	%		84	%
	Foreign		15			16			16

Related_Party_Activity

Related Party Activity	12 Months Ended
	Dec. 31, 2013
Related Party Activity [Abstract]	'
Related Party Activity	'
	12. Related Party Activity
	During the years ended December 31, 2013, 2012 and 2011, the Company sold $361,000, $451,000 and $504,000, respectively, of product to a company of which a board member of the Company is an officer.  As of December 31, 2013 and 2012, the Company had an accounts receivable balance due of $14,000 and $39,000, respectively, from this related party.  In addition, the Company purchases product from this related party and during the years ended December 31, 2013, 2012 and 2011 the Company purchased $10,000, $10,000 and $15,000, respectively, of product from this related party.  As of December 31, 2013 and 2012, the Company had an accounts payable balance due of $-0- to this related party.

Dependence_on_Key_Suppliers

Dependence on Key Suppliers	12 Months Ended
	Dec. 31, 2013
Dependence on Key Suppliers [Abstract]	'
Dependence on Key Suppliers	'
	13. Dependence on Key Suppliers
	King Pharmaceuticals
	The Company purchases certain key components from single-source suppliers.  Any significant component delay or interruption could require the Company to qualify new sources of supply, if available, and could have a material adverse effect on the Company’s financial condition and results of operations.  The Company purchases its requirements for thrombin (a component in the Hemostat products) under a Thrombin-JMI Supply Agreement entered into with King Pharmaceuticals, Inc. (King) on January 9, 2007.  Under the terms of the Thrombin-JMI Supply Agreement, King agrees to manufacture and supply thrombin to the Company on a non-exclusive basis.  The Thrombin-JMI Supply Agreement does not contain any minimum purchase requirements.  King agrees to supply the Company with such quantity of thrombin as the Company may order at a fixed price throughout the term of the Thrombin-JMI Supply Agreement as adjusted for inflation, variations in potency and other factors.  The Thrombin-JMI Supply Agreement has an initial term of 10 years, followed by successive automatic one-year extensions, subject to termination by the parties under certain circumstances, including: (i) termination by King without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to the Company, and (ii) termination by the Company without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to King provided that the Device Supply Agreement, which the Company also entered into with King on January 9, 2007, has expired on its terms or the parties have agreed to terminate it.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	14. Commitments and Contingencies
	All legal cost related to litigation are charged to operations as incurred, except settlements which are expensed when a claim is probable and estimable.
	Boston Scientific Corporate Litigation
	On May 16, 2013, the Company filed a patent infringement complaint in the United States District Court for the District of Minnesota against Boston Scientific Corporation (Boston Scientific).  The complaint alleges that Boston Scientific has infringed three of the Company’s patents concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla™ guide extension catheter, which received FDA 510(k) clearance in March 2013.  The Company is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter, as well as damages for lost profits and legal costs.  On June 10, 2013, the Company filed a motion for preliminary injunction asking the court to enjoin Boston Scientific’s manufacture and sale of the Guidezilla catheter during the pendency of the litigation.  On July 11, 2013, Boston Scientific filed its answer and counterclaim, alleging the Company’s patents are invalid, that the Guidezilla catheter does not infringe, and that the Company’s manufacture and sale of its GuideLiner catheter violates a U.S. patent owned by Boston Scientific that has recently expired.  The counterclaim seeks unspecified damages and payment of Boston Scientific’s attorney’s fees, expenses and costs.  On December 9, 2013, the District Court granted the Company’s motion for a preliminary injunction prohibiting Boston Scientific from making, using, offering for sale or selling its Guidezilla catheter during the pendency of the parties’ on-going patent infringement litigation.  On December 12, 2013, the District Court stayed the preliminary injunction to permit it to consider whether to permit Boston Scientific to move for reconsideration of the preliminary injunction.  On December 23, 2013, the District Court denied Boston Scientific’s request for permission to file a motion to reconsider the preliminary injunction and lifted the stay on the preliminary injunction effective January 13, 2014.  On December 27, 2013, Boston Scientific filed a motion with the United States Court of Appeals for the Federal Circuit for a stay, pending appeal, of the District Court’s preliminary injunction order and an interim stay pending the Federal Circuit’s consideration of the motion.  On January 8, 2014, the Federal Circuit issued an order denying Boston Scientific’s motion for an interim stay of the preliminary injunction.  On January 13, 2014, the preliminary injunction became effective prohibiting Boston Scientific from making, using, offering for sale or selling the Guidezilla guide extension catheter in the United States during the pendency of the patent litigation, currently scheduled to be ready for trial on or after March 2015.  On January 17, 2014, the Federal Circuit issued an order denying Boston Scientific’s motion for a stay of the preliminary injunction pending appeal.  The preliminary injunction order remains subject to an appeal by Boston Scientific before the Federal Circuit.
	Governmental Proceedings
	On June 28, 2011, the Company received a subpoena from the U.S. Attorney’s Office for the Western District of Texas under the Health Insurance Portability & Accountability Act of 1996 (HIPAA) requesting the production of documents related to Vari-Lase products, and in particular the use of the Vari-Lase Short Kit for the treatment of perforator veins.  Subsequently, the Company learned that the U.S. Attorney’s Office has commenced a criminal investigation of the same matter.  The Vari-Lase Short Kit has been sold under a 510(k) clearance for the treatment of incompetence and reflux of superficial veins in the lower extremity since 2007 with total U.S. sales through December 31, 2013 of approximately $479,000 (0.1% of the Company’s total U.S. sales for such period) and has not been the subject of any reported serious adverse clinical event.  On August 14, 2012, the United States District Court for the Western District of Texas unsealed a qui tam complaint that had been filed on November 19, 2010 by Desalle Bui, a former sales employee of the Company, which is the basis for the U.S. Attorney’s civil investigation, to which the federal government, after three extensions of time, elected to intervene.  The complaint contains allegations of off-label promotion of Vari-Lase products for the treatment of perforator veins, re-use of single-use Vari-Lase products and kickbacks to physicians, resulting in alleged damages to the government of approximately $20 million.  An amended complaint limited to allegations of off-label promotion of the Vari-Lase Short Kit resulting in an unspecified amount of damages and penalties was filed by the U.S. Attorney’s Office in December 2012.  On January 22, 2014, the Company agreed with the U.S. Attorney’s Office to settle the civil lawsuit.  The terms of the settlement are that the Company will make a payment of $520,000, the Company will make no admission of fault or liability, and the U.S. Attorney’s Office will dismiss the civil lawsuit with prejudice and release all civil claims that were, or could have been, brought against the Company in the civil lawsuit.  Settlement of the civil lawsuit will have no effect upon the criminal investigation, which the Company expects will continue.
	From time to time, the Company is involved in additional legal proceedings arising in the normal course of business.  As of the date of this report the Company is not a party to any legal proceeding not described in this section in which an adverse outcome would reasonably be expected to have a material adverse effect on the Company’s results of operations or financial condition.
	King Agreements
	On January 9, 2007, the Company entered into a License Agreement and a Device Supply Agreement with King (see Note 13).  King was acquired by Pfizer, Inc. on February 28, 2011.  Under the License Agreement, the Company licensed the exclusive rights to the Company’s products Thrombi-Pad®, Thrombi-Gel® and Thrombi-Paste® to King in exchange for a one-time license fee.  Under the Device Supply Agreement, the Company agreed to manufacture the licensed products for sale to King in exchange for an initial payment.  The unamortized license fee was $610,000, $815,000 and $1,019,000 at December 31, 2013, 2012 and 2011, respectively.  Amortization of the deferred revenue will be $204,000 per year for the remainder of the 10-year license period.  The amortization of license fee was $205,000, $204,000, and $3,222,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	Nicolai, GmbH Agreement
	Effective April 1, 2008, the Company entered into a five-year distribution agreement with Nicolai GmbH.  In connection with this distribution agreement, the Company received 500,000 Euros from Nicolai GmbH, which was deferred and was being recognized ratably over the five-year term of the distribution agreement.
	The agreement included provisions requiring the Company to pay Nicolai GmbH specific amounts if the Company terminated the distribution agreement prior to the end of the five-year term.  The Company did not terminate the distribution agreement prior to the termination date.  The unamortized license fee was $-0-, $36,000 and $182,000 at December 31, 2013, 2012 and 2011, respectively.  The amortization of license fee was $36,000, $146,000 and $145,000 for the years ended December 31, 2013, 2012 and 2011, respectively.

Business_Combinations_and_Asse

Business Combinations and Asset Acquisitions	12 Months Ended
	Dec. 31, 2013
Business Combinations and Asset Acquisitions [Abstract]	'
Business Combinations and Asset Acquisitions	'
	15. Business Combinations and Asset Acquisitions
	During the first quarter of fiscal year 2010, the Company adopted ASC 805, Business Combinations, related to business combinations.  This authoritative guidance establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling interests in the acquiree and the goodwill acquired.  The underlying purchase method of accounting for acquisitions was retained, but the new guidance incorporates a number of changes.  These changes include the capitalization of purchased in-process research and development, expensing of acquisition related costs and the recognition of contingent purchase price consideration at fair value at the acquisition date.
	When the Company acquires another company or a group of assets, the purchase price is allocated, as applicable, among in-process research and development, other identifiable intangible assets, net tangible assets and the remainder, if any, is recognized as goodwill, as required by U.S. GAAP.  Goodwill represents the excess of the aggregate purchase price over the fair value of net assets of acquired businesses, which is not amortized in accordance with ASC 350, Intangibles-Goodwill and Other.  The values assigned to other identifiable intangible assets are based on valuations as determined by the Company or independent third party appraisers.  The techniques used by these appraisers include estimating the future cash flows of each project or technology and discounting the net cash flows back to their present values utilizing an appropriate risk-adjusted rate of return (discount rate).  The discount rate used is determined at the time of the acquisition in accordance with accepted valuation methods.
	Shepherd Scientific, Inc.
	On December 21, 2012, the Company acquired the assets relating to the Teirstein Edge™ device organizer and AngioAssist™ docking station from Shepherd Scientific, Inc. (Shepherd Scientific).  Under the terms of the agreement, the Company agreed to pay Shepherd Scientific a total of $500,000, which was paid on December 21, 2012 at closing.  The Teirstein Edge assists in the organization of guidewires and catheters during interventional procedures, while the AngioAssist facilitates the introduction of guidewires into catheters and atherectomy burrs.
	The Company accounted for the transaction as a business combination in the fourth quarter of 2012.   In accordance with ASC 805 the purchase price is being allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Purchased technology	$	170,000
	Inventory and equipment		70,000
	Other intangibles		50,000
	Goodwill		210,000
		$	500,000
	Amortizable Acquired Assets
	Purchased technology.  Purchased technology consists of $170,000 of developed technology acquired.  The technology was valued using the income method utilizing a discounted cash flow model.  The Company is amortizing the technology assets on a straight line basis over their estimated useful life of nine years.
	Other intangibles.  Other intangibles consist of $30,000 representing trademarks and trade names relating to the Teirstein Edge and AngioAssist products and $20,000 representing customer relationships.  The customer relationships relate to the ability to sell existing and future services to existing customers of Shepherd Scientific.  The fair value of trademarks and trade names and customer relationships has been estimated using the income method utilizing a discounted cash flow model. The Company is amortizing the trademark and trade name intangible assets on a straight line basis over their estimated useful life of approximately ten years.  The customer relationship intangible assets are being amortized on a straight line basis over nine years.
	The weighted average amortization period for total amortizable intangible assets acquired in connection with the acquisition of the Teirstein Edge and AngioAssist products is nine years.
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired.  The establishment of goodwill was primarily due to the expected revenue growth that is attributable to increased market penetration from future customers.  All of the goodwill is expected to be deductible for income tax purposes.
	With the exception of sales to one customer, the Company was the sole U.S. distributor of Teirstein Edge and AngioAssist products prior to the acquisition.  The Company has seen sales increase slightly during 2013, but expects to realize additional revenue and improved margins in the coming years as all remaining older inventory has been sold.
	St. Jude Medical, Cardiology Division, Inc.
	On August 16, 2012, the Company acquired the assets related to the Venture wire control catheter from St. Jude Medical, Cardiology Division, Inc. (“St. Jude Medical”).  Under the terms of the agreement, the Company agreed to pay St. Jude Medical a total of $3,000,000, consisting of $2,250,000 paid in cash at August 16, 2012 and $750,000 paid in cash on April 17, 2013, upon the successful completion of the transfer of the manufacturing processes from St. Jude Medical to the Company.  The Venture wire control catheter is used as a deflectable tip catheter for steering a 0.014 inch guidewire via the arterial system to the coronary or peripheral vasculature.  This acquisition provides the Company with additional products that are sold directly into the Company’s existing customer base to generate incremental revenue.
	The Company accounted for the transaction as a business combination in the third quarter of 2012.   In accordance with ASC 805 the purchase price is being allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Purchased technology	$	850,000
	Other intangibles		500,000
	Inventory and equipment		189,000
	Goodwill		1,461,000
		$	3,000,000
	Amortizable Acquired Assets
	Purchased technology.  Purchased technology consists of $850,000 of developed technology acquired.  The technology was valued using the income method utilizing a discounted cash flow model.  The Company started amortizing the technology assets on a straight line basis over their estimated useful life of nine years once the Company started selling the products in the second quarter of 2013.
	Other intangibles.  Other intangibles consist of $220,000 representing trademarks and trade names relating to the Venture wire control catheter products and $280,000 representing customer relationships.  The customer relationships relate to the ability to sell existing and future products and services to existing customers of St. Jude Medical.  The fair value of trademarks and trade names and customer relationships has been estimated using the income method utilizing a discounted cash flow model.  The Company started amortizing the trademark and trade name intangible assets on a straight line basis over their estimated useful life of approximately ten years once the Company started selling the products in the second quarter of 2013.  The customer relationship intangible assets are being amortized on a straight line basis over nine years.
	The weighted average amortization period for total amortizable intangible assets acquired in connection with the acquisition of the Venture wire control catheter products is nine years.
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired.  The establishment of goodwill was primarily due to the expected revenue growth associated with this new product for the Company and possibility of selling additional products to these new customers.  All of the goodwill is expected to be deductible for income tax purposes.
	The Company has recognized additional revenue of $1,573,000 and net earnings of approximately $1,021,000 relating to the sale of Venture wire control catheter through December 31, 2013.  The amount of additional revenue and net earnings is expected to increase in coming years now that the transfer of the manufacturing processes from St. Jude Medical to the Company is complete.
	Accumed Systems, Inc.
	On June 11, 2012, the Company acquired the assets related to the Accumed wrist positioning splint business from Accumed Systems, Inc. (“Accumed”).  Under the terms of the agreement, the Company paid Accumed a total of $1,500,000 at closing and no additional payments are required to be made.  The Accumed wrist positioning splint product consists of a plastic molded brace that simplifies arterial access by holding the wrist and forearm in an appropriate, comfortable position.  This acquisition provides the Company with an additional product that is sold directly into the Company’s existing customer base to generate incremental revenue.
	The Company accounted for the transaction as a business combination in the second quarter of 2012.   In accordance with ASC 805 the purchase price is being allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Purchased technology	$	740,000
	Other intangibles		190,000
	Inventory and equipment		8,000
	Goodwill		562,000
		$	1,500,000
	Amortizable Acquired Assets
	Purchased technology.  Purchased technology consists of $740,000 of developed technology acquired.  The technology was valued using the income method utilizing a discounted cash flow model.  The Company is amortizing the technology assets on a straight line basis over their estimated useful life of nine years.
	Other intangibles.  Other intangibles consist of $100,000 representing trademarks and trade names relating to the Accumed wrist positioning splint products and $90,000 representing customer relationships.  The customer relationships relate to the ability to sell existing and future products and services to existing customers of Accumed.  The fair value of trademarks and trade names and customer relationships has been estimated using the income method utilizing a discounted cash flow model.  The Company is amortizing the trademark and trade name intangible assets on a straight line basis over their estimated useful life of approximately ten years.  The customer relationship intangible assets are being amortized on a straight line basis over nine years.
	The weighted average amortization period for total amortizable intangible assets acquired in connection with the acquisition of the Accumed wrist positioning splint products is nine years.
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired.  The establishment of goodwill was primarily due to the expected revenue growth that is attributable to increased market penetration from future customers.  All of the goodwill is expected to be deductible for income tax purposes.
	The Company has recognized additional revenue of $1,211,000 and net earnings of approximately $497,000 relating to the sales of the Accumed wrist positioning splint products from June 11, 2012 through December 31, 2013.
	Dr. Pedro Silva and Affiliates
	On January 6, 2012, the Company entered into an agreement with Dr. Pedro Silva and his affiliates, whereby the Company paid $3,250,000 for the rights, patents and intellectual property relating to a two-lumen catheter for distal protection and material extraction used in the Company’s Pronto catheters.  Upon payment, the existing License Agreement between N.G.C. Medical S.p.A. and the Company has been deemed paid-in-full, and no future royalties will be owed on any sale of a Pronto catheter after December 31, 2011.
	The Company has accounted for the transaction as a non-business license acquisition in the first quarter of 2012.   In accordance with ASC 805, the purchase price was assigned to a license intangible asset equivalent to the cash amount paid on January 6, 2012, and no goodwill was recognized.  The Company is amortizing the license intangible on a straight-line basis over a period of ten years.
	Northeast Scientific
	On September 17, 2013, the Company entered into an eight-year reprocessing services agreement with Northeast Scientific, Inc. (NES), a FDA-registered reprocessor of medical devices, whereby the Company paid NES a non-refundable amount of $500,000 for the exclusive right to offer NES’ reprocessing services in the United States for a commercial medical device.  NES is pursuing FDA approval for its reprocessing services for the device.  In the event FDA approval is obtained prior to July 1, 2014, the Company is required under the terms of the agreement to pay NES a non-refundable amount $500,000.  If FDA approval is obtained on/or after July 1, 2014, the Company is required to pay NES a non-refundable amount of $400,000.  The agreement has an annual minimum unit termination clause, allowing NES to terminate the agreement if the Company does not meet certain annual minimums.
	The Company has accounted for the transaction as a non-business asset acquisition in the third quarter of 2013.  In accordance with ASC 805 the purchase price of $900,000 is being assigned to an intangible and no goodwill was recognized.  The Company recorded a $400,000 accrual in the third quarter of 2013 in addition to the $500,000 payment, as the Company believes the FDA approval will occur after July 1, 2014.  The Company will begin amortizing the intangible asset on a per unit basis over the remaining term of the agreement once the Company begins to send units to NES to be reprocessed.
	On December 22, 2011, the Company entered into a license agreement with NES, a FDA-registered reprocessor of medical devices, whereby the Company acquired the exclusive rights to NES’ reprocessing services for the ClosureFAST radiofrequency catheter in the United States for a term of five years.  The ClosureFAST catheter is owned and marketed by VNUS Medical Technologies, Inc., a subsidiary of Covidien, and is used in the treatment of varicose veins.  Under the reprocessing service, the customer sends its used ClosureFAST catheters to NES, where they are inspected, cleaned, tested, repackaged, resterilized and shipped back to the customer. In exchange for the exclusive rights, the Company paid a total of $900,000 to NES and a former third party distributor on December 22, 2011.
	The Company has accounted for the transaction as a non-business asset acquisition in the fourth quarter of 2011.  In accordance with ASC 805 the purchase price is being assigned to an intangible and no goodwill was recognized.  The Company is amortizing the license intangible on a straight-line basis over the five-year term of the agreement.
	Zerusa Limited
	On January 27, 2011, the Company entered into an asset purchase agreement of substantially all the assets of Zerusa Limited (“Zerusa”), a Galway, Ireland based medical device company engaged in the manufacture and distribution of the Guardian® hemostasis valves.  Under the terms of the agreement the Company paid Zerusa a total of 3,121,000 Euros ($4,272,000), consisting of 2,850,000 Euros ($3,882,000) paid in cash at January 27, 2011 and 271,000 Euros ($390,000) which was paid on September 2, 2011.  The final payment amount was subject to adjustment based upon the value of inventory transferred.  The Guardian hemostasis valves are designed to maintain hemostasis during interventional catheterization procedures through a novel sealing system which allows simple introductions and removal of interventional devices while providing the option to lock guidewires in place.
	The Company accounted for the transaction as a business combination in the first quarter of 2011.   In accordance with ASC 805, the purchase price is being allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
Purchased technology	$	1,000,000
Other intangibles		800,000
Inventory and equipment		48,000
Goodwill		2,424,000
	$	4,272,000
Amortizable Acquired Assets
Purchased technology.  Purchased technology consists of $1,000,000 of developed technology acquired.  The technology was valued using the income method utilizing a discounted cash flow model. The Company is amortizing the technology assets on a straight line basis over their estimated useful lives of 11 years.
Other intangibles.  Other intangibles consist of $800,000 representing trademarks and trade names relating to the Guardian hemostasis valve products.  The fair value of trademarks and trade names has been estimated using the income method utilizing a discounted cash flow model. The Company is amortizing the trademark and trade name intangible assets on a straight line basis over their estimated useful life of approximately 11 years.
The weighted average amortization period for total amortizable intangible assets acquired in connection with the acquisition of the Guardian hemostasis valve products is 11 years.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired.  The establishment of goodwill was primarily due to the expected revenue growth that is attributable to increased market penetration from future customers.  All of the goodwill is expected to be deductible for income tax purposes.
Unaudited Supplemental Pro Forma Financial Information
The following unaudited supplemental pro forma information combines the Company’s results with those of Shepherd Scientific, St. Jude, Accumed and Zerusa as if the acquisitions had occurred at the beginning of each of the periods presented.  This unaudited pro forma information is not intended to represent or be indicative of the Company’s consolidated results of operations or financial condition that would have been reported for the periods presented had the acquisition been completed at the beginning of each of the periods presented, and should not be taken as indicative of the Company’s future consolidated results of operations or financial condition.
	Years
	Ended December 31,
	2013		2012
Revenue	$	110,498,000	$	99,051,000
Net earnings		11,142,000		9,779,000
Net earnings per share
Basic	$	0.68	$	0.61
Diluted	$	0.65	$	0.59
Certain pro forma adjustments have been made to reflect the impact of the purchase transaction, primarily consisting of amortization of intangible assets with determinable lives and income taxes to reflect the Company’s effective tax rate for the periods presented.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data) [Abstract]	'
Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data)	'
	16. Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data)
		Fourth		Third		Second		First
	2013	Quarter		Quarter		Quarter		Quarter
	Net revenue:
	Product	$	29,000	$	27,926	$	27,294	$	25,977
	License		72		83		59		87
	Total net revenue		29,072		28,009		27,353		26,064
	Selected costs and expenses:
	Costs of goods sold		9,724		9,197		8,538		8,697
	Operating earnings		4,731		4,020		4,442		2,904
	Net earnings		3,537		2,672		2,808		2,125
	Basic net earnings per share	$	0.21	$	0.16	$	0.17	$	0.13
	Diluted net earnings per share	$	0.2	$	0.16	$	0.17	$	0.13
		Fourth		Third		Second		First
	2012	Quarter		Quarter		Quarter		Quarter
	Net revenue:
	Product	$	25,215	$	24,465	$	24,650	$	23,706
	License		89		87		87		87
	Total net revenue		25,304		24,552		24,737		23,793
	Selected costs and expenses:
	Costs of goods sold		8,309		8,183		8,231		7,838
	Operating earnings		4,688		4,150		3,940		3,127
	Net earnings		3,051		2,565		2,384		1,909
	Basic net earnings per share	$	0.19	$	0.16	$	0.15	$	0.12
	Diluted net earnings per share	$	0.18	$	0.16	$	0.15	$	0.12

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	17. Subsequent Events
	The Company has evaluated subsequent events occurring after the date of the consolidated financial statements for events requiring recording or disclosure in the financial statements.

SCHEDULE_II_VALUATION_AND_QUAL

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2013
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS [Abstract]	'
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	'
	Vascular Solutions, Inc.
	SCHEDULE II
	VALUATION AND QUALIFYING ACCOUNTS
	YEARS ENDED DECEMBER 31, 2013, 2012 AND 2011
				Additions
				Charged
		Balance at		to Costs					Balance at
		Beginning		and		Less			End of
	Description	of Year		Expenses		Deductions			Year
	YEAR ENDED DECEMBER 31, 2013:
	Sales return allowance	$	55,000	$	20,000	$	(25,000	)	$	50,000
	Allowance for doubtful accounts		130,000		90,000		(70,000	)		150,000
	Total	$	185,000	$	110,000	$	(95,000	)	$	200,000
	YEAR ENDED DECEMBER 31, 2012:
	Sales return allowance	$	30,000	$	45,000	$	(20,000	)	$	55,000
	Allowance for doubtful accounts		120,000		75,000		(65,000	)		130,000
	Total	$	150,000	$	120,000	$	(85,000	)	$	185,000
	YEAR ENDED DECEMBER 31, 2011:
	Sales return allowance	$	45,000	$	30,000	$	(45,000	)	$	30,000
	Allowance for doubtful accounts		115,000		87,000		(82,000	)		120,000
	Total	$	160,000	$	117,000	$	(127,000	)	$	150,000

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Basis of Consolidation	'
	Basis of Consolidation
	The consolidated financial statements include the accounts of Vascular Solutions, Inc. and its wholly owned subsidiary Vascular Solutions Zerusa Limited, after elimination of intercompany accounts and transactions.
Segment Reporting	'
	Segment Reporting
	A business segment is a distinguishable component of an enterprise that is engaged in providing an individual product or service or a group of related products or services and that is subject to risks and returns that are different from those of other business segments.  The Company’s segments have similar economic characteristics and are similar in the nature of the products sold, type of customers, methods used to distribute the Company’s products and regulatory environment.  Management believes that the Company meets the criteria for aggregating its operating segments into a single reporting segment.
	The Company uses three product categories for reporting revenue.  The following table sets forth, for the periods indicated, net revenue by product category along with the percent change from the previous year:
			For Years Ended December 31,
			2013						2012						2011
						Percent						Percent					Percent
			Net Revenue			Change			Net Revenue			Change			Net Revenue		Change
	Catheter products		$	69,936,000			14	%	$	61,262,000			16	%	$	53,040,000		27	%
	Hemostat products			23,752,000			5	%		22,676,000			(2	%)		23,065,000		(6	%)
	Vein products			16,509,000			17	%		14,098,000			34	%		10,484,000		(4	%)
	Total product revenue			110,197,000			12	%		98,036,000			13	%		86,589,000		12	%
	License & Collaboration			301,000			(14	%)		350,000			(90	%)		3,367,000		229	%
	Total Net Revenue		$	110,498,000			12	%	$	98,386,000			9	%	$	89,956,000		15	%
Foreign Currency Translation and Transactions	'
	Foreign Currency Translation and Transactions
	The functional currency of the company's foreign operations is the applicable local currency.  The functional currency is translated into U.S. dollars for balance sheet accounts using current exchange rates in effect as of the balance sheet date and for revenue and expense accounts using a weighted-average exchange rate during the fiscal year.  The translation adjustments are deferred as a component of other comprehensive income within the consolidated statements of comprehensive income and the consolidated statements of shareholders' equity.  Gains or losses resulting from transactions denominated in foreign currencies are included in other income, net in the consolidated statements of earnings.
	The Company sells products to an international distributor in Germany at prices denominated in Euros.  As a result, the Company is exposed to foreign exchange movements during the time between the shipment of the product and payment.  The Company currently has terms of net 60 days with this distributor under the agreement providing for payment in Euros.
Comprehensive Earnings	'
	Comprehensive Earnings
	The components of comprehensive earnings are net earnings and the effects of foreign currency translation adjustments.  The accumulated other comprehensive earnings for the foreign currency translation adjustment at December 31, 2013 and 2012 was ($1,000) and ($150,000), respectively.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amount for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximates fair value due to the immediate or short-term maturity of these financial instruments.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of deferred tax assets and liabilities, as well as other amounts in the financial statements and accompanying notes.  Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company classifies all highly liquid investments with initial maturities of three months at the date of purchase or less as cash equivalents.  Cash equivalents consist of cash and money market funds and are stated at cost, which approximates market value.  The Company deposits its cash in high quality financial institutions.  The balances, at times, may exceed federally insured limits.
Credit Risk and Allowance for Doubtful Accounts	'
	Credit Risk and Allowance for Doubtful Accounts
	The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments.  This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay.  Accounts receivable over 60 days past due are considered past due.  The Company does not accrue interest on past due accounts receivable.  Receivables are written off only after all collection attempts have failed and are based on individual credit evaluation and the specific circumstances of the customer.  At December 31, 2013 and 2012, the allowance for doubtful accounts was $150,000 and $130,000, respectively.
	All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.  The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on its balance sheet.  At December 31, 2013 and 2012, the sales and return allowance was $50,000 and $55,000, respectively.
	Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $200,000 and $185,000 at December 31, 2013 and 2012, respectively.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market.   Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value.  Inventories are comprised of the following at December 31:
			2013			2012
	Raw materials		$	6,386,000		$	6,674,000
	Work-in-process			926,000			780,000
	Finished goods			6,690,000			6,283,000
			$	14,002,000		$	13,737,000
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost.  Depreciation is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Manufacturing equipment	1 to 8 years
	Office and computer equipment	1 to 5 years
	Furniture and fixtures	3 to 8 years
	Leasehold improvements	Shorter of useful life or remaining term of the lease
	Research and development equipment	3 to 7 years
	Building	30 years
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company will record impairment losses on long-lived assets when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount.  The amount of impairment loss recorded will be measured as the amount by which the carrying value of the assets exceeds the fair value of the assets.  To date, the Company has determined that no impairment of long-lived assets exists.
Revenue Recognition	'
	Revenue Recognition
	In the United States the Company sells its products and services directly to hospitals and clinics.  Revenue is recognized in accordance with generally accepted accounting principles as outlined in Accounting Standards Codification (“ASC”) 605-10-S99, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered.  The Company recognizes revenue as products are shipped based on FOB shipping point terms when title passes to customers.   The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.
	In all international markets, the Company sells its products to international distributors which subsequently resell the products to hospitals and clinics.  The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor.  The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor.  Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order.  Allowances are provided for estimated returns and costs at the time of shipment.  Sales and use taxes are reported on a net basis, excluding them from revenue.
	The Company’s revenues from license agreements and research collaborations are recognized when earned (see Note 14).  In accordance with ASC 605, for deliverables which contain multiple deliverables, the Company separates the deliverables into separate accounting units if they meet the following criteria: (i) the delivered items have a stand-alone value to the customer; (ii) the fair value of any undelivered items can be reliably determined; and (iii) if the arrangement includes a general right of return, delivery of the undelivered items is probable and substantially controlled by the seller.  Deliverables that do not meet these criteria are combined with one or more other deliverables into one accounting unit.  Revenue from each accounting unit is recognized based on the applicable accounting literature, primarily ASC 605.
	The Company currently has a license agreement with King Pharmaceuticals, Inc. (King), now a subsidiary of Pfizer, Inc., under which the Company licensed the exclusive rights of Thrombi-PadTM, Thrombi-Gel® and Thrombi-PasteTM products to King in exchange for a license fee.  The Company is amortizing the license fees on a straight-line basis over the projected 10 year economic life of the products.  The Company determines the economic life of the products under its license agreements by evaluating similar products the Company has launched or other similar products in the medical industry.  In addition, the Company had a five-year license agreement with Nicolai, GmbH in which the Company was amortizing the license fee on a straight-line basis over the five-year life of the agreement.  This agreement was fully amortized during 2013.
	As part of the agreements with King, the Company agreed to complete the development and conduct clinical studies for the Thrombi-Gel and Thrombi-Paste products, with the costs related to the clinical studies paid by King.  The Company was recognizing the collaboration revenue on this development agreement as it is earned in accordance with ASC 605.  On July 6, 2011, King notified the Company that King was terminating the development of the Thrombi-Paste products and terminating efforts to obtain the surgical indication for the Thrombi-Gel products (see Note 14).
	Starting in January 2012, the Company began to generate revenue from selling a reprocessing service for ClosureFAST radiofrequency catheters.  In accordance with ASC 605-45, the Company recognizes this revenue gross, with the amount paid to the supplier of the reprocessing service reflected as cost of sales.
	In addition, the Company has reviewed the provisions of ASC 808, Collaborative Arrangements, and the adoption of this ASC has had no impact on the amounts recorded under these agreements.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	In accordance with the ASC 605-45-45, the Company includes shipping and handling revenues in net sales and shipping and handling costs in cost of goods sold.
Research and Development Costs	'
	Research and Development Costs
	All research and development costs are charged to operations as incurred.
Warranty Costs	'
	Warranty Costs
	Certain of the Company’s products are covered by warranties against defects in material and workmanship for periods of up to 24 months.  The Company records a liability for warranty claims at the time of sale.  The amount of the liability is based on the amount the Company is charged from its original equipment manufacturer to cover the warranty period.  The original equipment manufacturers include a one year warranty with each product sold to
	the Company.  The Company records a liability for the uncovered warranty period offered to a customer, provided the warranty period offered exceeds the initial one year warranty period covered by the original equipment manufacturers.  Each of the Company’s manufacturer’s warranties cover the first year of service and as a result the Company’s exposure to uncovered warranty periods was minimal at December 31, 2013.
	Warranty provisions and claims for the years ended December 31, 2013, 2012 and 2011, were as follows:
			2013			2012			2011
	Beginning balance		$	29,000		$	23,000		$	13,000
	Warranty provisions			69,000			57,000			79,000
	Warranty claims			(75,000	)		(51,000	)		(69,000	)
	Ending balance		$	23,000		$	29,000		$	23,000
Advertising Costs	'
	Advertising Costs
	The Company follows the policy of charging production costs of advertising to expense as incurred.  Advertising expense was $119,000, $103,000 and $71,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company has various types of stock-based compensation plans.  These plans are administered by the Compensation Committee of the Board of Directors, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.  Refer to Notes 8 and 9 for additional information related to these stock-based compensation plans.
	The following amounts have been recognized as stock-based compensation expense in the Consolidated Statements of Operations:
			2013			2012			2011
	Stock-based compensation included in:
	Cost of goods sold		$	196,000		$	94,000		$	86,000
	Research and development			373,000			389,000			250,000
	Clinical and regulatory			322,000			313,000			239,000
	Sales and marketing			858,000			941,000			825,000
	General and administrative			1,594,000			1,246,000			850,000
			$	3,343,000		$	2,983,000		$	2,250,000
	The Company uses the Black-Scholes option-pricing model to estimate fair value of stock-based awards with the following weighted average assumptions:
			2013			2012			2011
	Stock Options and Awards:
	Expected life (years)			3.6			6.5			5.5
	Expected volatility			39	%		48	%		49	%
	Dividend yield			0	%		0	%		0	%
	Risk-free interest rate			0.86	%		1.21	%		2.12	%
	Employee Stock Purchase Plan:
	Expected life (years)			2			2			2
	Expected volatility			29	%		32	%		34	%
	Dividend yield			0	%		0	%		0	%
	Risk-free interest rate			0.32	%		0.28	%		0.47	%
	Restricted stock awards fair value is calculated as the market price on the date of grant for the years ended December 31, 2013, 2012 and 2011 and the fair value is amortized on a straight line basis over the requisite service period of four years for employee awards and one year for board of director awards.  The weighted average fair value of restricted stock awards granted during 2013, 2012 and 2011 was $16.31, $11.10 and $10.77, respectively.
	The weighted average fair value of stock options granted with an exercise price equal to the deemed stock price on the date of grant during 2012 and 2011 was $5.41 and $4.72, respectively.  There were no stock option grants during 2013.  The weighted average fair value of stock options granted with an exercise price greater than the deemed stock price on the date of grant during 2012 was $5.11.
	The Company calculates expected volatility for stock options and awards using historical volatility.  The starting point for the historical period used is based on a material change in the Company’s operations that occurred in the third quarter of 2003.  The Company uses a 10% forfeiture rate for key employees and a 15% forfeiture rate for non-key employees for stock options and awards.  The Company calculates expected volatility for employee stock purchase plan shares using historical volatility over a two-year period.  A two-year period is used to coincide with the maximum two-year offering period under the employee stock purchase plan.  The risk-free rates for the expected terms of the stock options and awards and the employee stock purchase plan is based on the U.S. Treasury yield curve in effect at the time of grant.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for under the liability method.  Deferred income taxes are provided for temporary differences between the financial reporting and the tax bases of assets and liabilities.  Deferred tax assets are reduced by a valuation allowance to the extent that realization of the related deferred tax asset is not assured.  If the Company determines in the future that it is more likely than not that the Company will realize all or a portion of the deferred tax assets, the Company will adjust the valuation allowance in the period the determination is made (see Note 7).
	When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained.  The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.  Tax positions taken are not offset or aggregated with other positions.  Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority.  The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
	The Company has recorded ASC 740, Income Taxes, reserves of $1,268,000 and $1,074,000 at December 31, 2013 and 2012.  The impact of tax related interest and penalties is recorded as a component of income tax expense.  At December 31, 2013, the Company has recorded $-0- for the payment of tax related interest and there were no tax penalties or interest recognized in the consolidated statements of earnings.
Net Earnings Per Common Share	'
	Net Earnings Per Common Share
	In accordance with ASC 260, Earnings Per Share, basic net earnings per common share is computed by dividing net earnings by the weighted average common shares outstanding during the periods presented.  Diluted net earnings per common share is computed by dividing net earnings by the weighted average common and potential dilutive common shares outstanding computed in accordance with the treasury stock method.
	The number of shares used in earnings per share computations is as follows for the years ended December 31:
			2013			2012			2011
	Weighted average common shares outstanding— basic			16,412,322			16,003,932			16,638,078
	Effect of dilutive securities			612,768			451,797			545,501
	Weighted average common shares outstanding— diluted			17,025,090			16,455,729			17,183,579
	The effect of dilutive securities in the above table excludes -0-, 270,000 and 70,000 of options for which the exercise price was higher than the average market price for the years ended December 31, 2013, 2012 and 2011, respectively.
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	Goodwill is reviewed for impairment annually on December 31st or more frequently if changes in circumstances or the occurrence of events suggest impairment exists using a two-step process.  In step 0, the Company can elect to perform an optional quantitative analysis and based on the results, skip the remaining two steps.  Consistent with prior years, in the current year the Company chose to skip step 0 and perform a quantitative analysis in Step 1.  In the step 1, the fair value of each reporting unit is compared to its carrying value, including goodwill.  If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized.  If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and the Company would then complete step 2 in order to measure the impairment loss.  In step 2, the Company would calculate the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets (including unrecognized intangible assets) of the reporting unit from the fair value of the reporting unit.  If the implied fair value of goodwill is less than the carrying value of goodwill, the Company would recognize an impairment loss, in the period identified, equal to the difference.  The Company has concluded that no impairment of goodwill existed as of December 31, 2013.
	Other intangible assets consist of purchased technology, trademark/tradenames, developed technology, customer relationships and licenses.  The Company reviewed intangible assets for impairment as changes in circumstances or the occurrence of events suggested the remaining value was not recoverable.
	Amortization on the intangibles is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Trademark/tradename	10 to 11 years
	Purchased and developed technology	9 to 11 years
	Customer relationships	9 years
	Licenses	5 to 10 years
Leases and Deferred Rent	'
	Leases and Deferred Rent
	On November 30, 2012, the Company closed on the purchase of an office building located next to the building which previously housed the Company’s principal executive offices.  The Company occupies approximately 23,000 square feet of the building and leases the remaining 47,000 square feet of the building to third-party tenants.
	In addition, during the year ended December 31, 2013 the Company also leased additional office and manufacturing space.  Leases are accounted for under the provisions of ASC 840, Leases, which requires that leases be evaluated and classified as operating or capital leases for financial reporting purposes.  As of December 31, 2013, all of the Company’s leases were accounted for as operating leases.  For leases that contain rent escalations, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between the rents paid and the straight-line rent as a deferred rent.  For any lease incentives the Company receives for items such as leasehold improvements, the Company records a deferred credit for the amount of the lease incentive and amortizes it over the lease term, which may or may not equal the amortization period of the leasehold improvements in accordance with ASC 840-20.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Net Revenue by Product Category	'
	The Company uses three product categories for reporting revenue.  The following table sets forth, for the periods indicated, net revenue by product category along with the percent change from the previous year:
			For Years Ended December 31,
			2013						2012						2011
						Percent						Percent					Percent
			Net Revenue			Change			Net Revenue			Change			Net Revenue		Change
	Catheter products		$	69,936,000			14	%	$	61,262,000			16	%	$	53,040,000		27	%
	Hemostat products			23,752,000			5	%		22,676,000			(2	%)		23,065,000		(6	%)
	Vein products			16,509,000			17	%		14,098,000			34	%		10,484,000		(4	%)
	Total product revenue			110,197,000			12	%		98,036,000			13	%		86,589,000		12	%
	License & Collaboration			301,000			(14	%)		350,000			(90	%)		3,367,000		229	%
	Total Net Revenue		$	110,498,000			12	%	$	98,386,000			9	%	$	89,956,000		15	%
Inventory	'
	Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market.   Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value.  Inventories are comprised of the following at December 31:
			2013			2012
	Raw materials		$	6,386,000		$	6,674,000
	Work-in-process			926,000			780,000
	Finished goods			6,690,000			6,283,000
			$	14,002,000		$	13,737,000
Property, Plant and Equipment	'
	Property, plant and equipment consist of the following at December 31:
			2013			2012
	Plant and equipment:
	Manufacturing equipment		$	12,019,000		$	10,174,000
	Buildings			6,407,000			6,407,000
	Office and computer equipment			2,798,000			2,265,000
	Research and development equipment			2,567,000			1,707,000
	Leasehold improvements			2,489,000			2,269,000
	Furniture and fixtures			1,039,000			782,000
	Building improvements			665,000			–
	Construction-in-process			658,000			977,000
				28,642,000			24,581,000
	Less accumulated depreciation and amortization			(14,055,000	)		(11,425,000	)
	Net plant and equipment			14,587,000			13,156,000
	Land			1,600,000			1,600,000
	Net property, plant and equipment		$	16,187,000		$	14,756,000
Warranty Provisions and Claims	'
	Warranty provisions and claims for the years ended December 31, 2013, 2012 and 2011, were as follows:
			2013			2012			2011
	Beginning balance		$	29,000		$	23,000		$	13,000
	Warranty provisions			69,000			57,000			79,000
	Warranty claims			(75,000	)		(51,000	)		(69,000	)
	Ending balance		$	23,000		$	29,000		$	23,000
Share-based Compensation Expense	'
	The following amounts have been recognized as stock-based compensation expense in the Consolidated Statements of Operations:
			2013			2012			2011
	Stock-based compensation included in:
	Cost of goods sold		$	196,000		$	94,000		$	86,000
	Research and development			373,000			389,000			250,000
	Clinical and regulatory			322,000			313,000			239,000
	Sales and marketing			858,000			941,000			825,000
	General and administrative			1,594,000			1,246,000			850,000
			$	3,343,000		$	2,983,000		$	2,250,000
Share-based Payment Award, Stock Options, Valuation Assumptions	'
	The Company uses the Black-Scholes option-pricing model to estimate fair value of stock-based awards with the following weighted average assumptions:
			2013			2012			2011
	Stock Options and Awards:
	Expected life (years)			3.6			6.5			5.5
	Expected volatility			39	%		48	%		49	%
	Dividend yield			0	%		0	%		0	%
	Risk-free interest rate			0.86	%		1.21	%		2.12	%
	Employee Stock Purchase Plan:
	Expected life (years)			2			2			2
	Expected volatility			29	%		32	%		34	%
	Dividend yield			0	%		0	%		0	%
	Risk-free interest rate			0.32	%		0.28	%		0.47	%
Weighted Average Number of Shares in Earnings Per Share Computations	'
	The number of shares used in earnings per share computations is as follows for the years ended December 31:
			2013			2012			2011
	Weighted average common shares outstanding— basic			16,412,322			16,003,932			16,638,078
	Effect of dilutive securities			612,768			451,797			545,501
	Weighted average common shares outstanding— diluted			17,025,090			16,455,729			17,183,579
Estimated Useful Life of Intangible Assets	'
	Amortization on the intangibles is provided on a straight-line basis over the estimated useful lives of the assets as follows:
	Trademark/tradename	10 to 11 years
	Purchased and developed technology	9 to 11 years
	Customer relationships	9 years
	Licenses	5 to 10 years

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Acquired Intangible Assets	'
	Balances of acquired intangible assets as of December 31, 2013 were as follows:
		Carrying			Accumulated		Net
		Amount			Amortization
	Amortizing intangibles:
	Purchased and developed technology	$	8,140,000		$	2,360,000	$	5,780,000
	Purchased licenses		5,050,000			1,010,000		4,040,000
	Trademark / tradename		2,210,000			592,000		1,618,000
	Customer relationships		640,000			133,000		507,000
	Foreign currency translation adjustments		16,000			18,000		(2,000	)
		$	16,056,000		$	4,113,000	$	11,943,000
	Balances of acquired intangible assets as of December 31, 2012 were as follows:
		Carrying			Accumulated		Net
		Amount			Amortization
	Amortizing intangibles:
	Purchased and developed technology	$	7,960,000		$	1,555,000	$	6,405,000
	Purchased licenses		4,150,000			505,000		3,645,000
	Trademark / tradename		2,170,000			390,000		1,780,000
	Customer relationships		620,000			74,000		546,000
	Foreign currency translation adjustments		(50,000	)		1,000		(51,000	)
		$	14,850,000		$	2,525,000	$	12,325,000
Expected Amortization Expense	'
	Based on the intangibles assets as of December 31, 2013, future amortization expense was as follows:
	2014	$	1,734,000
	2015		1,824,000
	2016		1,817,000
	2017		1,644,000
	2018		1,644,000
	Thereafter		3,280,000
		$	11,943,000
Goodwill	'
	The following table provides a summary of additions and disposals of goodwill for each reporting period:
	Balance at December 31, 2011	$	8,117,000
	Acquisition of Accumed wrist positioning splint		562,000
	Acquisition of St. Jude Medical’s Venture wire control catheter		1,444,000
	Acquisition of Shepherd Scientific’s AngioAssist & Teirstein Edge		210,000
	Foreign currency translation adjustments		54,000
	Balance at December 31, 2012	$	10,387,000
	Acquisition of Disposable Vein Hook		59,000
	Foreign currency translation adjustments		86,000
	Balance at December 31, 2013	$	10,532,000

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property, plant and equipment consist of the following at December 31:
		2013			2012
	Plant and equipment:
	Manufacturing equipment	$	12,019,000		$	10,174,000
	Buildings		6,407,000			6,407,000
	Office and computer equipment		2,798,000			2,265,000
	Research and development equipment		2,567,000			1,707,000
	Leasehold improvements		2,489,000			2,269,000
	Furniture and fixtures		1,039,000			782,000
	Building improvements		665,000			–
	Construction-in-process		658,000			977,000
			28,642,000			24,581,000
	Less accumulated depreciation and amortization		(14,055,000	)		(11,425,000	)
	Net plant and equipment		14,587,000			13,156,000
	Land		1,600,000			1,600,000
	Net property, plant and equipment	$	16,187,000		$	14,756,000

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Future Minimum Rental Payments for Operating Leases	'
	Future minimum lease commitments under the operating leases as of December 31, 2013 were as follows:
	2014	$	908,000
	2015		682,000
	2016		–
	2017		–
	2018		–
	Thereafter		–
		$	1,590,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Deferred Taxes with Finite Lives	'
	At December 31, 2013, the Company had recorded the following components of deferred taxes with a finite life:
					Expiration
		2013			Date
	Federal and Minnesota research and development tax credit carryforwards	$	4,766,000		Beginning in 2014
	Foreign research and development tax credit carryforwards		93,000		Do not expire
	Foreign operations operating loss carryforwards		643,000		Do not expire
Unrecognized Tax Benefits Roll Forward	'
	A reconciliation of the beginning and ending amount of unrecognized tax benefit is as follows:
	Balance at December 31, 2011	$	1,020,000
	Increases as a result of tax positions taken during a prior period		–
	Increases as a result of tax positions taken during the current period		54,000
	Reductions as a result of lapse of the applicable statute of limitations		–
	Decreases relating to settlements with taxing authorities		–
	Balance at December 31, 2012	$	1,074,000
	Increases as a result of tax positions taken during a prior period		–
	Increases as a result of tax positions taken during the current period		223,000
	Reductions as a result of lapse of the applicable statute of limitations		(29,000	)
	Decreases relating to settlements with taxing authorities		–
	Balance at December 31, 2013	$	1,268,000
Deferred Tax Assets and Liabilities	'
	The components of the Company’s deferred tax assets and liabilities as of December 31, 2013 and 2012 are as follows:
		2013				2012
	Deferred tax assets:
	Tax credit carryforwards	$	4,766,000			$	5,610,000
	Stock-based compensation		1,151,000				1,514,000
	Net operating loss carryforwards		–				1,288,000
	Federal and state AMT credits		985,000				996,000
	Inventory reserve		609,000				557,000
	Depreciation and amortization		624,000				520,000
	Accrued compensation		578,000				487,000
	Deferred revenue		229,000				320,000
	Legal settlement		196,000				–
	Foreign operations net operating loss carryforwards		96,000				47,000
	Other		115,000				130,000
	Gross deferred tax assets		9,349,000				11,469,000
	Deferred tax liability relating to amortization		(584,000	)			(336,000	)
	Net deferred taxes assets before reserve for uncertain tax positions and valuation allowances		8,765,000				11,133,000
	Reserve for uncertain tax positions		(882,000	)			(906,000	)
	Less valuation allowances		(144,000	)			(1,434,000	)
	Net deferred tax asset	$	7,739,000			$	8,793,000
		2013				2012
	Deferred taxes recorded on the balance sheet:
	Net deferred tax assets – current	$	6,000,000			$	6,800,000
	Net deferred tax assets – long-term		1,739,000				1,993,000
	Net deferred tax assets	$	7,739,000			$	8,793,000
Effective Income Tax Rate Reconciliation	'
	Reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows:
		2013				2012			2011
	Tax at statutory rate		34	%			34	%		34	%
	State income taxes, net of federal benefit		4.4				6.2			5.8
	Permanent differences		(0.8	)			1.9			1.2
	Change in valuation reserve		0.2				0.2			(1.1	)
	R&D credits generated		(4.2	)			(1.1	)		(3.1	)
	Reserve for uncertain tax positions		0.9				0.1			0.6
	Foreign operations tax rate difference		(0.5	)			(0.7	)		–
	Disallowed federal R&D credits at 12.31.12		(1.9	)			–			–
	Other adjustments		(1.0	)			(3.0	)		0.6
	Effective income tax rate		31.1	%			37.6	%		38	%
		2013				2012			2011
	Current taxes		26.8	%			12.8	%		3.8	%
	Deferred taxes		6.6				26.1			34.7
	Benefit from foreign operation tax rates		(0.5	)			(0.7	)		–
	Benefit from domestic manufacturers deduction		(1.8	)			(0.6	)		(0.5	)
	Effective income tax rate		31.1	%			37.6	%		38	%

Stock_Options_and_Restricted_S1

Stock Options and Restricted Shares (Tables)	12 Months Ended
	Dec. 31, 2013
Stock Options and Restricted Shares [Abstract]	'
Option Activity	'
	Option activity is summarized as follows:
	Shares
	Available
	for Grant						Weighted
	(exclusive of						Average		Aggregate
	restricted		Plan Options		Exercise		Exercise		Intrinsic
		shares issued)			Outstanding			Price			Price			Value
	Balance at December 31, 2010		3,878,000			837,000		$	0.78–$10.98		$	6.62
	Shares reserved		500,000			–			–			–
	Granted		(70,000	)		70,000			11.72			11.72
	Exercised		–			(87,000	)		0.84– 9.46			4
	Forfeited		–			–			–			–
	Expired		19,000			(19,000	)		0.84– 9.46			5.45
	Balance at December 31, 2011		4,327,000			801,000		$	0.78–$11.72		$	7.38
	Shares reserved		(1,900,000	)		–			–			–
	Granted		(500,000	)		500,000			11.03– 15.03			12.89
	Exercised		–			(158,000	)		0.84– 10.28			3.1
	Forfeited		–			–			–			–
	Expired		–			–			–			–
	Balance at December 31, 2012		1,927,000			1,143,000		$	0.78–$15.03		$	10.38
	Shares reserved		500,000			–			–			–
	Granted		–			–			–			–
	Exercised		–			(354,000	)		0.78– 11.72			7.86
	Forfeited		–			–			–			–
	Expired		1,000			(1,000	)		0.84– 5.74			5.38
	Balance at December 31, 2013		2,428,000			788,000		$	6.36–$15.03		$	11.52		$	9,164,000
	Exercisable at December 31, 2013					421,000					$	9.8		$	5,625,000
Stock Options Outstanding	'
	The following table summarizes information about stock options outstanding at December 31, 2013:
			Options Outstanding									Options Exercisable
						Weighted
			Outstanding			Average			Weighted			Exercisable
			as of			Remaining			Average			as of			Weighted
	Range of		December 31,			Contractual			Exercise			December 31,			Average
	Exercise Prices		2013			Life			Price			2013			Exercise Price
	$ 6.36–$ 7.88			76,000			3.9		$	6.83			76,000		$	6.83
	7.89– 9.46			115,000			1.5			9.44			115,000			9.44
	9.47– 10.98			67,000			4.2			10.08			67,000			10.08
	10.99– 12.03			260,000			8			11.58			163,000			11.32
	12.04– 13.03			90,000			8.1			13.03			–			–
	13.04– 15.03			180,000			8.1			14.53			–			–
				788,000			6.3		$	11.52			421,000		$	9.8
Restricted Share Activity	'
	Restricted share activity is summarized as follows:
					Weighted Average
					Grant Date Fair
		Shares
		Outstanding			Value
	Balance at December 31, 2010		463,000		$	8.49
	Granted		274,000			10.77
	Vested		(132,000	)		8.72
	Forfeited		(38,000	)		10.05
	Balance at December 31, 2011		567,000		$	9.43
	Granted		245,000			11.1
	Vested		(167,000	)		8.12
	Forfeited		(32,000	)		10.67
	Balance at December 31, 2012		613,000		$	10.39
	Granted		199,000			16.31
	Vested		(208,000	)		9.96
	Forfeited		(16,000	)		11.22
	Balance at December 31, 2013		588,000		$	12.52

Concentrations_of_Credit_and_O1

Concentrations of Credit and Other Risks (Tables)	12 Months Ended
	Dec. 31, 2013
Concentrations of Credit and Other Risks [Abstract]	'
Product Revenue by Geographic Destination as a Percentage of Total Product Revenues	'
	Product revenue by geographic destination as a percentage of total product revenues were as follows for the years ended December 31:
		2013			2012			2011
	Domestic		85	%		84	%		84	%
	Foreign		15			16			16

Business_Combinations_and_Asse1

Business Combinations and Asset Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Business Acquisition [Line Items]	'
Consolidated Results of Operation or Financial Condition	'
	The following unaudited supplemental pro forma information combines the Company’s results with those of Shepherd Scientific, St. Jude, Accumed and Zerusa as if the acquisitions had occurred at the beginning of each of the periods presented.  This unaudited pro forma information is not intended to represent or be indicative of the Company’s consolidated results of operations or financial condition that would have been reported for the periods presented had the acquisition been completed at the beginning of each of the periods presented, and should not be taken as indicative of the Company’s future consolidated results of operations or financial condition.
		Years
		Ended December 31,
		2013		2012
	Revenue	$	110,498,000	$	99,051,000
	Net earnings		11,142,000		9,779,000
	Net earnings per share
	Basic	$	0.68	$	0.61
	Diluted	$	0.65	$	0.59
Shepherd Scientific, Inc. [Member]	'
Business Acquisition [Line Items]	'
Purchase Price Allocation	'
	The purchase price was allocated as follows:
	Purchased technology	$	170,000
	Inventory and equipment		70,000
	Other intangibles		50,000
	Goodwill		210,000
		$	500,000
St. Jude Medical, Cardiology Division Inc [Member]	'
Business Acquisition [Line Items]	'
Purchase Price Allocation	'
	The purchase price was allocated as follows:
	Purchased technology	$	850,000
	Other intangibles		500,000
	Inventory and equipment		189,000
	Goodwill		1,461,000
		$	3,000,000
Accumed Systems, Inc [Member]	'
Business Acquisition [Line Items]	'
Purchase Price Allocation	'
	The purchase price was allocated as follows:
	Purchased technology	$	740,000
	Other intangibles		190,000
	Inventory and equipment		8,000
	Goodwill		562,000
		$	1,500,000
Zerusa Limited [Member]	'
Business Acquisition [Line Items]	'
Purchase Price Allocation	'
	The purchase price was allocated as follows:
	Purchased technology	$	1,000,000
	Other intangibles		800,000
	Inventory and equipment		48,000
	Goodwill		2,424,000
		$	4,272,000

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data) [Abstract]	'
Quarterly Financial Data	'
		Fourth		Third		Second		First
	2013	Quarter		Quarter		Quarter		Quarter
	Net revenue:
	Product	$	29,000	$	27,926	$	27,294	$	25,977
	License		72		83		59		87
	Total net revenue		29,072		28,009		27,353		26,064
	Selected costs and expenses:
	Costs of goods sold		9,724		9,197		8,538		8,697
	Operating earnings		4,731		4,020		4,442		2,904
	Net earnings		3,537		2,672		2,808		2,125
	Basic net earnings per share	$	0.21	$	0.16	$	0.17	$	0.13
	Diluted net earnings per share	$	0.2	$	0.16	$	0.17	$	0.13
		Fourth		Third		Second		First
	2012	Quarter		Quarter		Quarter		Quarter
	Net revenue:
	Product	$	25,215	$	24,465	$	24,650	$	23,706
	License		89		87		87		87
	Total net revenue		25,304		24,552		24,737		23,793
	Selected costs and expenses:
	Costs of goods sold		8,309		8,183		8,231		7,838
	Operating earnings		4,688		4,150		3,940		3,127
	Net earnings		3,051		2,565		2,384		1,909
	Basic net earnings per share	$	0.19	$	0.16	$	0.15	$	0.12
	Diluted net earnings per share	$	0.18	$	0.16	$	0.15	$	0.12

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Category

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of product categories

'

'

'

'

'

'

'

'

3

'

'

'

Product

$29,000,000

$27,926,000

$27,294,000

$25,977,000

$25,215,000

$24,465,000

$24,650,000

$23,706,000

$110,197,000

$98,036,000

$86,589,000

'

License

72,000

83,000

59,000

87,000

89,000

87,000

87,000

87,000

301,000

350,000

3,367,000

'

Total net revenue

29,072,000

28,009,000

27,353,000

26,064,000

25,304,000

24,552,000

24,737,000

23,793,000

110,498,000

98,386,000

89,956,000

'

Total product revenue, percentage change (in hundredths)

'

'

'

'

'

'

'

'

12.00%

13.00%

12.00%

'

Total net revenue, percentage change, (in hundredths)

'

'

'

'

'

'

'

'

12.00%

9.00%

15.00%

'

Statement of Other Comprehensive Income [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Foreign currency translation adjustment

'

'

'

'

'

'

'

'

-1,000

-150,000

'

'

Valuation and Qualifying Accounts Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Number of days before considered past due

'

'

'

'

'

'

'

'

'60 days

'

'

'

Restocking Charge

'

'

'

'

'

'

'

'

20.00%

'

'

'

Balance at End of Year

200,000

'

'

'

185,000

'

'

'

200,000

185,000

150,000

160,000

Inventory Disclosure [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

Raw materials

6,386,000

'

'

'

6,674,000

'

'

'

6,386,000

6,674,000

'

'

Work in process

926,000

'

'

'

780,000

'

'

'

926,000

780,000

'

'

Finished goods

6,690,000

'

'

'

6,283,000

'

'

'

6,690,000

6,283,000

'

'

Total inventory

14,002,000

'

'

'

13,737,000

'

'

'

14,002,000

13,737,000

'

'

Allowance for Doubtful Accounts [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Valuation and Qualifying Accounts Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Balance at End of Year

150,000

'

'

'

130,000

'

'

'

150,000

130,000

'

'

Sales Return Allowance [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Valuation and Qualifying Accounts Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Balance at End of Year

50,000

'

'

'

55,000

'

'

'

50,000

55,000

30,000

45,000

Catheter Products [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Product

'

'

'

'

'

'

'

'

69,936,000

61,262,000

53,040,000

'

Total product revenue, percentage change (in hundredths)

'

'

'

'

'

'

'

'

14.00%

16.00%

27.00%

'

Hemostat Products [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Product

'

'

'

'

'

'

'

'

23,752,000

22,676,000

23,065,000

'

Total product revenue, percentage change (in hundredths)

'

'

'

'

'

'

'

'

5.00%

-2.00%

-6.00%

'

Vein Products [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Product

'

'

'

'

'

'

'

'

16,509,000

14,098,000

10,484,000

'

Total product revenue, percentage change (in hundredths)

'

'

'

'

'

'

'

'

17.00%

34.00%

-4.00%

'

License and Collaboration [Member]

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

License

'

'

'

'

'

'

'

'

$301,000

$350,000

$3,367,000

'

Total product revenue, percentage change (in hundredths)

'

'

'

'

'

'

'

'

-14.00%

-90.00%

229.00%

'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies, Part Two (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Warranty costs [Abstract]	'	'	'
Standard product warranty timeframe	'24 months	'	'
Movement in Standard Product Warranty Accrual [Roll Forward]	'	'	'
Beginning balance	$29,000	$23,000	$13,000
Warranty provisions	69,000	57,000	79,000
Warranty claims	-75,000	-51,000	-69,000
Ending balance	23,000	29,000	23,000
Advertising Costs [Abstract]	'	'	'
Advertising expense	$119,000	$103,000	$71,000
Thrombi Pad [Member]	'	'	'
Revenue Recognition, Amortization of License Fee [Line Items]	'	'	'
Years to amortize license fees	'10 years	'	'
Thrombi Paste [Member]	'	'	'
Revenue Recognition, Amortization of License Fee [Line Items]	'	'	'
Years to amortize license fees	'10 years	'	'
Thrombi Gel [Member]	'	'	'
Revenue Recognition, Amortization of License Fee [Line Items]	'	'	'
Years to amortize license fees	'10 years	'	'
Nicolai, GmbH [Member]	'	'	'
Revenue Recognition, Amortization of License Fee [Line Items]	'	'	'
Years to amortize license fees	'5 years	'	'
Manufacturing Equipment [Member] | Minimum [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'1 year	'	'
Manufacturing Equipment [Member] | Maximum [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'8 years	'	'
Office and Computer Equipment [Member] | Minimum [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'1 year	'	'
Office and Computer Equipment [Member] | Maximum [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'5 years	'	'
Furniture and Fixtures [Member] | Minimum [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'3 years	'	'
Furniture and Fixtures [Member] | Maximum [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'8 years	'	'
Leasehold Improvements [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life of leasehold improvements	'Shorter of useful life or remaining term of the lease	'	'
Research and Development Equipment [Member] | Minimum [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'3 years	'	'
Research and Development Equipment [Member] | Maximum [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'7 years	'	'
Building [Member]	'	'	'
Property and Equipment [Line Items]	'	'	'
Useful life	'30 years	'	'

Summary_of_Significant_Account5

Summary of Significant Accounting Policies, Part Three (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	sqft
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	$3,343,000	$2,983,000	$2,250,000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Restricted stock awards granted, weighted average grant date fair value (in dollars per share)	$16.31	$11.10	$10.77
Stock options granted, weighted average exercise price (in dollars per share)	'	$5.41	$4.72
Stock options granted, weighted average exercise price greater than deemed stock price (in dollars per share)	'	$5.11	'
Expected forfeiture rate for key employees (in hundredths)	10.00%	'	'
Expected forfeiture rate for non-key employees (in hundredths)	15.00%	'	'
Income Tax Uncertainties [Abstract]	'	'	'
Unrecognized tax benefits	1,268,000	1,074,000	1,020,000
Net income per share [Abstract]	'	'	'
Weighted average common shares outstanding - basic (in shares)	16,412,322	16,003,932	16,638,078
Effect of diluted securities (in shares)	612,768	451,797	545,501
Weighted average common shares outstanding - diluted (in shares)	17,025,090	16,455,729	17,183,579
Antidilutive securities excluded from computation of earnings per share (in shares)	0	270,000	70,000
Leases and Deferred Rent [Abstract]	'	'	'
Area company occupies (in square feet)	23,000	'	'
Area occupied by current tenants (in square feet)	47,000	'	'
Minimum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'9 years	'	'
Maximum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'11 years	'	'
Trademark/Tradename [Member] | Minimum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'10 years	'	'
Trademark/Tradename [Member] | Maximum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'11 years	'	'
Purchased Technology [Member] | Minimum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'9 years	'	'
Purchased Technology [Member] | Maximum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'11 years	'	'
Customer Relationships [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'9 years	'	'
Licenses [Member] | Minimum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'5 years	'	'
Licenses [Member] | Maximum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Useful lives	'10 years	'	'
Stock Options and Awards [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected life	'3 years 7 months 6 days	'6 years 6 months	'5 years 6 months
Expected volatility (in hundredths)	39.00%	48.00%	49.00%
Dividend yield (in hundredths)	0.00%	0.00%	0.00%
Risk free interest rate (in hundredths)	0.86%	1.21%	2.12%
Employee Stock Purchase Plan [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected life	'2 years	'2 years	'2 years
Expected volatility (in hundredths)	29.00%	32.00%	34.00%
Dividend yield (in hundredths)	0.00%	0.00%	0.00%
Risk free interest rate (in hundredths)	0.32%	0.28%	0.47%
Cost of Goods Sold [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	196,000	94,000	86,000
Research and Development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	373,000	389,000	250,000
Clinical and Regulatory [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	322,000	313,000	239,000
Sales and Marketing [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	858,000	941,000	825,000
General and Administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation expense	$1,594,000	$1,246,000	$850,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 27, 2011

Dec. 31, 2012

Jun. 11, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 21, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Zerusa Limited [Member]

Accumed Systems, Inc [Member]

Accumed Systems, Inc [Member]

St Jude Medical [Member]

Shepherd Scientific, Inc. [Member]

Shepherd Scientific, Inc. [Member]

Disposable Vein Hook [Member]

Maximum [Member]

Minimum [Member]

Purchased Technology [Member]

Purchased Technology [Member]

Purchased Technology [Member]

Purchased Technology [Member]

Purchased Licenses [Member]

Purchased Licenses [Member]

Purchased Licenses [Member]

Purchased Licenses [Member]

Trademark/Tradename [Member]

Trademark/Tradename [Member]

Trademark/Tradename [Member]

Trademark/Tradename [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Foreign Currency Translation Adjustments [Member]

Foreign Currency Translation Adjustments [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization expense

$1,572,000

$1,393,000

$831,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful lives

'

'

'

'

'

'

'

'

'

'

'11 years

'9 years

'

'

'11 years

'9 years

'

'

'10 years

'5 years

'

'

'11 years

'10 years

'9 years

'

'

'

Remaining amortization period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

Carrying amount

16,056,000

14,850,000

'

'

'

'

'

'

'

'

'

'

8,140,000

7,960,000

'

'

5,050,000

4,150,000

'

'

2,210,000

2,170,000

'

'

640,000

620,000

16,000

-50,000

Accumulated amortization

4,113,000

2,525,000

'

'

'

'

'

'

'

'

'

'

2,360,000

1,555,000

'

'

1,010,000

505,000

'

'

592,000

390,000

'

'

133,000

74,000

18,000

1,000

Net

11,943,000

12,325,000

'

'

'

'

'

'

'

'

'

'

5,780,000

6,405,000

'

'

4,040,000

3,645,000

'

'

1,618,000

1,780,000

'

'

507,000

546,000

-2,000

-51,000

Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2014

1,734,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

1,824,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

1,817,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

1,644,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018

1,644,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Thereafter

3,280,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total

11,943,000

12,325,000

'

'

'

'

'

'

'

'

'

'

5,780,000

6,405,000

'

'

4,040,000

3,645,000

'

'

1,618,000

1,780,000

'

'

507,000

546,000

-2,000

-51,000

Goodwill [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance

10,387,000

8,117,000

'

2,424,000

'

562,000

'

'

210,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchased licenses & acquisitions

'

'

'

'

562,000

'

1,444,000

210,000

'

59,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Foreign currency translation adjustments

86,000

54,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ending balance

$10,532,000

$10,387,000

$8,117,000

$2,424,000

'

$562,000

'

'

$210,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	$28,642,000	$24,581,000
Less accumulated depreciation and amortization	-14,055,000	-11,425,000
Net plant and equipment	14,587,000	13,156,000
Land	1,600,000	1,600,000
Net property, plant and equipment	16,187,000	14,756,000
Manufacturing Equipment [Member]	'	'
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	12,019,000	10,174,000
Buildings [Member]	'	'
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	6,407,000	6,407,000
Leasehold Improvements [Member]	'	'
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	2,489,000	2,269,000
Office and Computer Equipment [Member]	'	'
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	2,798,000	2,265,000
Research and Development Equipment [Member]	'	'
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	2,567,000	1,707,000
Construction in Progress [Member]	'	'
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	658,000	977,000
Furniture and Fixtures [Member]	'	'
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	1,039,000	782,000
Building Improvements [Member]	'	'
Property and Equipment [Line Items]	'	'
Plant and Equipment, Gross	$665,000	$0

Lines_of_Credit_Details

Lines of Credit (Details) (Lines of Credit [Member], USD $)	12 Months Ended
	Dec. 31, 2013
	Covenant
	Time
Lines of Credit [Member]	'
Line of Credit Facility [Line Items]	'
Credit agreement period	'1 year
Maximum credit limit	$10,000,000
Quarterly loan repayment (in hundredths)	0.13%
Line of credit facility, number of covenants	1
Numerator cash flow leverage ratio, maximum	2.5
Denominator cash flow leverage ratio, maximum	1
Multiple of annual lease expense for covenant calculation	6
Rolling period for computation of covenant (in months)	'12 months
Line of credit facility, amount outstanding	$0

Leases_Details

Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Leases [Abstract]	'	'	'
Rent expense	$1,350,000	$1,273,000	$1,297,000
Future Minimum Payments Due [Abstract]	'	'	'
2014	908,000	'	'
2015	682,000	'	'
2016	0	'	'
2017	0	'	'
2018	0	'	'
Thereafter	0	'	'
Total	$1,590,000	'	'
Minnesota [Member]	'	'	'
Operating Leases [Line Items]	'	'	'
Number of buildings under lease	2	'	'
Number of square-feet in the buildings under an operating lease	106,000	'	'
Ireland [Member]	'	'	'
Operating Leases [Line Items]	'	'	'
Number of buildings under lease	1	'	'
Number of square-feet in the buildings under an operating lease	1,150	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of Deferred Taxes with Finite Life [Abstract]	'	'	'
Federal and Minnesota research and development tax credit carryforwards	$4,766,000	'	'
Operating loss carryforwards	93,000	'	'
Foreign operations operating loss carryforwards	643,000	'	'
Federal and Minnesota research and development tax credit carryforwards, Earliest Expiration Date	31-Dec-14	'	'
Operating Loss Carryforwards, Earliest Expiration Date	'Do not Expire	'	'
Foreign operations operating loss carryforwards, Expiration Dates	'Do not Expire	'	'
Allowance relating to research and development tax credit carryforwards	144,000	'	'
Tax Related [Line Items]	'	'	'
Income tax expense (benefit)	4,941,000	5,983,000	5,960,000
Earnings (loss) before income tax	16,083,000	15,892,000	15,699,000
Increase (decrease) in valuation allowance	-1,290,000	-683,000	185,000
Stock option and employee stock purchase plan tax deductions	2,116,000	1,181,000	'
Stock option and employee stock purchase plan tax benefits against "additional paid-in capital" and reduced taxes payable	2,084,000	1,135,000	'
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Beginning balance	1,074,000	1,020,000	'
Increases as a result of tax positions taken during a prior period	0	0	'
Increases as a result of tax positions taken during the current period	223,000	54,000	'
Reductions as a result of lapse of the applicable statute of limitations	-29,000	0	'
Decreases relating to settlements with taxing authorities	0	0	'
Ending balance	1,268,000	1,074,000	1,020,000
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]	'	'	'
Tax at statutory rate (in hundredths)	34.00%	34.00%	34.00%
State income taxes, net of federal benefit (in hundredths)	4.40%	6.20%	5.80%
Permanent differences (in hundredths)	-0.80%	1.90%	1.20%
Change in valuation reserve (in hundredths)	0.20%	0.20%	-1.10%
R&D credits generated (in hundredths)	-4.20%	-1.10%	-3.10%
Reserve for uncertain tax positions (in hundredths)	0.90%	0.10%	0.60%
Foreign operations tax rate difference	-0.50%	-0.70%	0.00%
Disallowed federal R&D credits at 12.31.12	-1.90%	0.00%	0.00%
Other adjustments (in hundredths)	-1.00%	-3.00%	0.60%
Effective income tax rate (in hundredths)	31.10%	37.60%	38.00%
Current taxes (in hundredths)	26.80%	12.80%	3.80%
Deferred taxes (in hundredths)	6.60%	26.10%	34.70%
Benefit from foreign operation tax rates (in hundredths)	-0.50%	-0.70%	0.00%
Benefit from domestic manufacturers deduction	-1.80%	-0.60%	-0.50%
Deferred Tax Assets [Abstract]	'	'	'
Tax credit carryforwards	4,766,000	5,610,000	'
Stock-based compensation	1,151,000	1,514,000	'
Net operating loss carryforwards	0	1,288,000	'
Federal and state AMT credits	985,000	996,000	'
Inventory reserve	609,000	557,000	'
Depreciation and amortization	624,000	520,000	'
Accrued compensation	578,000	487,000	'
Deferred revenue	229,000	320,000	'
Legal settlement	196,000	0	'
Foreign operations net operating loss carryforwards	96,000	47,000	'
Other	115,000	130,000	'
Gross deferred tax assets	9,349,000	11,469,000	'
Deferred tax liability relating to amortization	-584,000	-336,000	'
Net deferred taxes assets before reserve for uncertain tax positions and valuation allowances	8,765,000	11,133,000	'
Reserve for uncertain tax positions	-882,000	-906,000	'
Less Valuation allowances	-144,000	-1,434,000	'
Net deferred tax asset	7,739,000	8,793,000	'
Deferred taxes recorded on the balance sheet [Abstract]	'	'	'
Net deferred tax assets - current	6,000,000	6,800,000	'
Net deferred tax assets - long-term	1,739,000	1,993,000	'
Net deferred tax assets	7,739,000	8,793,000	'
Period of cumulative earnings	'3 years	'	'
Domestic [Member]	'	'	'
Tax Related [Line Items]	'	'	'
Earnings (loss) before income tax	16,080,000	15,594,000	'
Foreign [Member]	'	'	'
Tax Related [Line Items]	'	'	'
Earnings (loss) before income tax	($108,000)	$298,000	'

Stock_Options_and_Restricted_S2

Stock Options and Restricted Shares (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Shares reserved for Stock Option Plan	5,500,000	'	'
Weighted Average Exercise Price [Roll Forward]	'	'	'
Granted, weighted average exercise price (in dollars per share)	'	$5.41	$4.72
Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'
Granted (in dollars per share)	$16.31	$11.10	$10.77
Shares available for grant, balance at end of period (in shares)	1,021,000	'	'
Unrecognized compensation costs for stock options	$2,010,000	'	'
Expected forfeiture rate for key employees (in hundredths)	10.00%	'	'
Expected forfeiture rate for non-key employees (in hundredths)	15.00%	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Options Outstanding as of end of period (in shares)	788,000	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'6 years 3 months 18 days	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$11.52	'	'
Options Exercisable as of end of period (in shares)	421,000	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$9.80	'	'
$6.36 to $7.88 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit (in dollars per share)	$6.36	'	'
Exercise price range, upper range limit (in dollars per share)	$7.88	'	'
Options Outstanding as of end of period (in shares)	76,000	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'3 years 10 months 24 days	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$6.83	'	'
Options Exercisable as of end of period (in shares)	76,000	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$6.83	'	'
$7.89 to $9.46 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit (in dollars per share)	$7.89	'	'
Exercise price range, upper range limit (in dollars per share)	$9.46	'	'
Options Outstanding as of end of period (in shares)	115,000	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'1 year 6 months	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$9.44	'	'
Options Exercisable as of end of period (in shares)	115,000	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$9.44	'	'
$9.47 to $10.98 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit (in dollars per share)	$9.47	'	'
Exercise price range, upper range limit (in dollars per share)	$10.98	'	'
Options Outstanding as of end of period (in shares)	67,000	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'4 years 2 months 12 days	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$10.08	'	'
Options Exercisable as of end of period (in shares)	67,000	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$10.08	'	'
$10.99 to $12.03 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit (in dollars per share)	$10.99	'	'
Exercise price range, upper range limit (in dollars per share)	$12.03	'	'
Options Outstanding as of end of period (in shares)	260,000	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'8 years	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$11.58	'	'
Options Exercisable as of end of period (in shares)	163,000	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$11.32	'	'
$12.04 to $13.03 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit (in dollars per share)	$12.04	'	'
Exercise price range, upper range limit (in dollars per share)	$13.03	'	'
Options Outstanding as of end of period (in shares)	90,000	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'8 years 1 month 6 days	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$13.03	'	'
Options Exercisable as of end of period (in shares)	0	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$0	'	'
$13.04 to $15.03 [Member]	'	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'	'
Exercise price range, lower range limit (in dollars per share)	$13.04	'	'
Exercise price range, upper range limit (in dollars per share)	$15.03	'	'
Options Outstanding as of end of period (in shares)	180,000	'	'
Options Outstanding, Weighted Average Remaining Contractual Life	'8 years 1 month 6 days	'	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$14.53	'	'
Options Exercisable as of end of period (in shares)	0	'	'
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$0	'	'
Chief Executive Officer [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Number of successive periods to awards vesting	5	'	'
Escalation (in dollars per share)	$1	'	'
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Terms of award	'10 years	'	'
Vesting period, incentive stock options	'4 years	'	'
Award vesting period, nonqualified stock options	'1 year	'	'
Number of months after employment until the options are terminated	'3 months	'	'
Vesting period for options	'1 year	'	'
Forfeiture rate on options granted (in hundredths)	0.00%	'	'
Plan Options Outstanding [Roll Forward]	'	'	'
Balance at beginning of year (in shares)	1,143,000	801,000	837,000
Shares reserved (in shares)	0	0	0
Granted (in shares)	0	500,000	70,000
Exercised (in shares)	-354,000	-158,000	-87,000
Forfeited (in shares)	0	0	0
Expired (in shares)	-1,000	0	-19,000
Balance at end of year (in shares)	788,000	1,143,000	801,000
Weighted Average Exercise Price [Roll Forward]	'	'	'
Balance at beginning of year, weighted average exercise price (in dollars per share)	$10.38	$7.38	$6.62
Reserved, weighted average exercise price (in dollars per share)	$0	$0	$0
Granted, weighted average exercise price (in dollars per share)	$0	$12.89	$11.72
Exercised, weighted average exercise price (in dollars per share)	$7.86	$3.10	$4
Forfeited, weighted average exercise price (in dollars per share)	$0	$0	$0
Expired, weighted average exercise price (in dollars per share)	$5.38	$0	$5.45
Balance at end of period, weighted average exercise price (in dollars per share)	$11.52	$10.38	$7.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'
Outstanding balance, aggregate intrinsic value	9,164,000	'	'
Exercisable at end of period (in shares)	421,000	'	'
Exercisable, weighted average exercise price (in dollars per share)	$9.80	'	'
Exercisable, intrinsic value at end of period	5,625,000	'	'
Exercise price, reserved (in dollars per share)	$0	$0	$0
Exercise price, forfeited (in dollars per share)	$0	$0	$0
Options, exercisable, weighted average remaining contractual term	'4 years 9 months 18 days	'	'
Total intrinsic value of options exercised	3,057,000	1,464,000	677,000
Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'
Shares available for grant, balance at beginning (in shares)	1,927,000	4,327,000	3,878,000
Shares reserved (in shares)	500,000	-1,900,000	500,000
Granted (in shares)	0	-500,000	-70,000
Exercised (in shares)	0	0	0
Forfeited (in shares)	0	0	0
Expired (in shares)	1,000	0	19,000
Shares available for grant, balance at end of period (in shares)	2,428,000	1,927,000	4,327,000
Weighted average period for recognizing unrecognized compensation costs	'1 year 0 months 4 days	'	'
Stock Options [Member] | Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'
Exercise price, beginning balance (in dollar per share)	$0.78	$0.78	$0.78
Exercise price, granted (in dollars per share)	'	$11.03	$11.72
Exercise price, exercised (in dollars per share)	$0.78	$0.84	$0.84
Exercise price, expired (in dollars per share)	$0.84	'	$0.84
Exercise price, ending balance (in dollar per share)	$6.36	$0.78	$0.78
Stock Options [Member] | Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'
Exercise price, beginning balance (in dollar per share)	$15.03	$11.72	$10.89
Exercise price, granted (in dollars per share)	'	$15.03	$11.72
Exercise price, exercised (in dollars per share)	$11.72	$10.28	$9.46
Exercise price, expired (in dollars per share)	$5.74	'	$9.46
Exercise price, ending balance (in dollar per share)	$15.03	$15.03	$11.72
Restricted Stock [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Vesting period for options	'1 year	'	'
Share Outstanding [Roll Forward]	'	'	'
Balance at beginning of year (in shares)	613,000	567,000	463,000
Granted (in shares)	199,000	245,000	274,000
Vested (in shares)	-208,000	-167,000	-132,000
Forfeited (in shares)	-16,000	-32,000	-38,000
Balance at end of period (in shares)	588,000	613,000	567,000
Weighted Average Grant Date Fair Value [Roll Forward]	'	'	'
Balance at beginning of year (in dollars per share)	$10.39	$9.43	$8.49
Granted (in dollars per share)	$16.31	$11.10	$10.77
Vested (in dollars per share)	$9.96	$8.12	$8.72
Forfeited (in dollars per share)	$11.22	$10.67	$10.05
Balance at beginning of year (in dollars per share)	$12.52	$10.39	$9.43
Shares available for grant, balance at end of period (in shares)	1,407,000	'	'
Unrecognized compensation costs for restricted shares	$1,287,000	'	'
Weighted average period for recognizing unrecognized compensation costs	'3 years 0 months 29 days	'	'
Expected forfeiture rate for directors (in hundredths)	0.00%	'	'
Expected forfeiture rate for key employees (in hundredths)	10.00%	'	'
Expected forfeiture rate for non-key employees (in hundredths)	15.00%	'	'

Employee_Stock_Purchase_Plan_D

Employee Stock Purchase Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Stock Purchase Plan [Abstract]	'	'	'
Number of reserved shares (in shares)	2,700,000	'	'
Minimum percentage of compensation to contribute (in hundredths)	1.00%	'	'
Maximum percentage of compensation to contribute (in hundredths)	10.00%	'	'
Discount to market (in hundredths)	15.00%	'	'
Maximum number of shares available to purchase per purchasing period, per employee (in shares)	2,000	'	'
Stock issued (in shares)	124,100	114,100	115,500
Shares available for issuance (in shares)	965,000	'	'
Aggregate compensation cost not yet recognized, ESPP	$340,000	'	'
Period for recognition	'0 years 9 months 18 days	'	'

Employee_Retirement_Savings_Pl1

Employee Retirement Savings Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Retirement Savings Plan [Abstract]	'	'	'
Employees maximum contribution percentage of annual compensation (in hundredths)	50.00%	'	'
Employer matching contribution, percent (in hundredths)	25.00%	'	'
Maximum annual contribution per employee, matched by employer, percent (in hundredths)	5.00%	'	'
Expense recorded	$243,000	$204,000	$194,000

Concentrations_of_Credit_and_O2

Concentrations of Credit and Other Risks (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Concentration Risk [Line Items]	'	'	'
Threshold for reporting customers revenues by customer (in hundredths)	10.00%	10.00%	10.00%
Threshold for reporting customers gross receivables by customer (in hundredths)	10.00%	10.00%	'
Domestic [Member] | Product Revenue [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk (in hundredths)	85.00%	84.00%	84.00%
Foreign [Member] | Product Revenue [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk (in hundredths)	15.00%	16.00%	16.00%

Related_Party_Activity_Details

Related Party Activity (Details) (Director [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Director [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Revenue from related parties	$361,000	$451,000	$504,000
Accounts receivable	14,000	39,000	'
Purchases from related party	10,000	10,000	15,000
Accounts payable	$0	$0	'

Dependence_on_Key_Suppliers_De

Dependence on Key Suppliers (Details)	12 Months Ended
	Dec. 31, 2013
Kings Pharmaceuticals [Abstract]	'
Initial agreement period	'10 years
Contract extension period	'1 year
Period of written notice to supplier	'5 years

Commitments_and_Contingencies_

Commitments and Contingencies (Details)

3 Months Ended

12 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Apr. 01, 2008

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Governmental Proceedings [Member]

King Agreements [Member]

King Agreements [Member]

King Agreements [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

Governmental Proceedings [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total U.S. sales, maximum

$29,000,000

$27,926,000

$27,294,000

$25,977,000

$25,215,000

$24,465,000

$24,650,000

$23,706,000

$110,197,000

$98,036,000

$86,589,000

$479,000

'

'

'

'

'

'

'

Total U.S. sales, percentage (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

0.10%

'

'

'

'

'

'

'

Damages from product defects to government

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

Terms of settlement of litigation

'

'

'

'

'

'

'

'

'

'

'

520,000

'

'

'

'

'

'

'

Amortization period for license fee

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'5 years

'

'

'

Amortization of license fee

'

'

'

'

'

'

'

'

'

'

'

'

205,000

204,000

3,223,000

36,000

146,000

145,000

'

Unamortized license fee

'

'

'

'

'

'

'

'

'

'

'

'

$610,000

$815,000

$1,019,000

$0

$36,000

$182,000

€ 500,000

Business_Combinations_and_Asse2

Business Combinations and Asset Acquisitions (Details)

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

16 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

18 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 21, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 21, 2012

Dec. 31, 2013

Dec. 21, 2012

Aug. 16, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 16, 2012

Dec. 31, 2013

Aug. 16, 2012

Jun. 11, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Jun. 11, 2012

Dec. 31, 2013

Jun. 11, 2012

Jan. 06, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 02, 2011

Sep. 02, 2011

Jan. 27, 2011

Jan. 27, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

Trademarks [Member]

Trademarks [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Licenses [Member]

Licenses [Member]

Shepherd Scientific, Inc. [Member]

Shepherd Scientific, Inc. [Member]

Shepherd Scientific, Inc. [Member]

Shepherd Scientific, Inc. [Member]

Shepherd Scientific, Inc. [Member]

Shepherd Scientific, Inc. [Member]

Shepherd Scientific, Inc. [Member]

St. Jude Medical, Cardiology Division, Inc. [Member]

St. Jude Medical, Cardiology Division, Inc. [Member]

St. Jude Medical, Cardiology Division, Inc. [Member]

St. Jude Medical, Cardiology Division, Inc. [Member]

St. Jude Medical, Cardiology Division, Inc. [Member]

St. Jude Medical, Cardiology Division, Inc. [Member]

St. Jude Medical, Cardiology Division, Inc. [Member]

St. Jude Medical, Cardiology Division, Inc. [Member]

Accumed Systems, Inc [Member]

Accumed Systems, Inc [Member]

Accumed Systems, Inc [Member]

Accumed Systems, Inc [Member]

Accumed Systems, Inc [Member]

Accumed Systems, Inc [Member]

Accumed Systems, Inc [Member]

Accumed Systems, Inc [Member]

Dr. Pedro Silva and Affiliates [Member]

Dr. Pedro Silva and Affiliates [Member]

Northeast Scientific [Member]

Northeast Scientific [Member]

Northeast Scientific [Member]

Northeast Scientific [Member]

Zerusa Limited [Member]

Zerusa Limited [Member]

Zerusa Limited [Member]

Zerusa Limited [Member]

Zerusa Limited [Member]

Zerusa Limited [Member]

Zerusa Limited [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Technology [Member]

Trademarks [Member]

Trademarks [Member]

Customer Relationships [Member]

Customer Relationships [Member]

USD ($)

USD ($)

Technology [Member]

Trademarks [Member]

Trademarks [Member]

Customer Relationships [Member]

Customer Relationships [Member]

USD ($)

USD ($)

Technology [Member]

Trademarks [Member]

Trademarks [Member]

Customer Relationships [Member]

Customer Relationships [Member]

USD ($)

Licenses [Member]

USD ($)

Licenses [Member]

Prior to July 1, 2014 [Member]

On or After July 1, 2014 [Member]

USD ($)

EUR (€)

USD ($)

EUR (€)

Technology [Member]

Trademarks [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Purchase price allocation [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, cost of acquired entity, purchase price, total

'

'

'

'

'

'

'

'

'

$500,000

'

'

'

'

'

'

$3,000,000

'

'

'

'

'

'

'

$1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,272,000

€ 3,121,000

'

'

'

Acquired indefinite-lived intangible asset, amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,250,000

'

'

'

'

'

'

'

'

'

'

'

'

Acquired finite-lived intangible asset, amount

16,056,000

14,850,000

'

2,210,000

2,170,000

640,000

620,000

5,050,000

4,150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

'

'

'

'

'

'

'

'

'

Amount paid For exclusive rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

500,000

400,000

'

'

'

'

'

'

'

Business acquisition, cost of acquired entity, cash paid

820,000

7,500,000

6,621,000

'

'

'

'

'

'

'

'

'

'

'

'

'

2,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

390,000

271,000

3,882,000

2,850,000

'

'

'

Business acquisition cash payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition, purchase price allocation, liabilities assumed

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

Term of agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'8 years

'

'

'

'

'

'

'

'

'

'

Amount accrued for exclusive rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

Purchase price asset allocation [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchased technology

'

'

'

'

'

'

'

'

'

170,000

'

'

'

'

'

'

850,000

'

'

'

'

'

'

'

740,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

Inventory and equipment

'

'

'

'

'

'

'

'

'

70,000

'

'

'

'

'

'

189,000

'

'

'

'

'

'

'

8,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

48,000

'

'

'

'

Other intangibles

'

'

'

'

'

'

'

'

'

50,000

'

'

'

30,000

'

20,000

500,000

'

'

'

'

220,000

'

280,000

190,000

'

'

'

'

100,000

'

90,000

'

'

'

'

'

'

'

'

800,000

'

'

'

'

Goodwill

10,532,000

10,387,000

8,117,000

'

'

'

'

'

'

210,000

'

'

'

'

'

'

1,461,000

'

'

'

'

'

'

'

562,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,424,000

'

'

'

'

Total asset purchase price allocation

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,272,000

'

'

'

'

Estimated useful life of intangible assets

'

'

'

'

'

'

'

'

'

'

'9 years

'9 years

'10 years

'

'9 years

'

'

'9 years

'

'9 years

'10 years

'

'9 years

'

'

'9 years

'

'9 years

'10 years

'

'9 years

'

'

'10 years

'5 years

'5 years

'

'

'

'

'

'

'11 years

'11 years

'11 years

Additional revenue relating to Venture Wire Control Catheter

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,573,000

'

'

'

'

'

'

'

1,211,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional net earnings relating to Venture Wire Control Catheter

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,021,000

'

'

'

'

'

'

'

497,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proforma consolidated results of operations or financial condition [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue

110,498,000

99,051,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net earnings

$11,142,000

$9,779,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net earnings per share [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Basic (in dollar per share)

$0.68

$0.61

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Diluted (in dollar per share)

$0.65

$0.59

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited, in Thousands, Except per Share Data) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net revenue [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Product	$29,000,000	$27,926,000	$27,294,000	$25,977,000	$25,215,000	$24,465,000	$24,650,000	$23,706,000	$110,197,000	$98,036,000	$86,589,000
License	72,000	83,000	59,000	87,000	89,000	87,000	87,000	87,000	301,000	350,000	3,367,000
Total net revenue	29,072,000	28,009,000	27,353,000	26,064,000	25,304,000	24,552,000	24,737,000	23,793,000	110,498,000	98,386,000	89,956,000
Selected costs and expenses [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Cost of goods sold	9,724,000	9,197,000	8,538,000	8,697,000	8,309,000	8,183,000	8,231,000	7,838,000	36,156,000	32,561,000	29,844,000
Operating earnings	4,731,000	4,020,000	4,442,000	2,904,000	4,688,000	4,150,000	3,940,000	3,127,000	16,097,000	15,905,000	15,586,000
Net earnings	$3,537,000	$2,672,000	$2,808,000	$2,125,000	$3,051,000	$2,565,000	$2,384,000	$1,909,000	$11,142,000	$9,909,000	$9,739,000
Basic net earnings per share (in dollars per share)	$0.21	$0.16	$0.17	$0.13	$0.19	$0.16	$0.15	$0.12	$0.68	$0.62	$0.59
Diluted net earnings per share (in dollars per share)	$0.20	$0.16	$0.17	$0.13	$0.18	$0.16	$0.15	$0.12	$0.65	$0.60	$0.57

SCHEDULE_II_VALUATION_AND_QUAL1

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Balance at Beginning of Year	$185,000	$150,000	$160,000
Additions Charged to Cost and Expenses	110,000	120,000	117,000
Less Deductions	-95,000	-85,000	-127,000
Balance at End of Year	200,000	185,000	150,000
Sales Return Allowance [Member]	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Balance at Beginning of Year	55,000	30,000	45,000
Additions Charged to Cost and Expenses	20,000	45,000	30,000
Less Deductions	-25,000	-20,000	-45,000
Balance at End of Year	50,000	55,000	30,000
Allowance for Doubtful Accounts [Member]	'	'	'
Movement in Valuation Allowances and Reserves [Roll Forward]	'	'	'
Balance at Beginning of Year	130,000	120,000	115,000
Additions Charged to Cost and Expenses	90,000	75,000	87,000
Less Deductions	-70,000	-65,000	-82,000
Balance at End of Year	$150,000	$130,000	$120,000